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ABSTRACT
A number of beta-adrenergic blocking agents were examined for their 
in vivo effects on the rat hepatic microsomal mixed-function oxygenase 
system to determine their potential for microsomal enzyme induction 
and epigenetic carcinogenesis. The method is based on previous findings 
that pretreatment of rats with chemical carcinogens preferentially 
stimulates biphenyl 2-hydroxylase and ethoxyresorufin O-deethylase, 
mixed-function oxidase activities catalysed by cytochrome P-448,the form 
of microsomal cytochrome known to be formed by chemical carcinogens.
None of the beta-adrenergic blockers studied with the exception of 
propranolol and pronethalol, stimulated these cytochrome P-448-mediated 
enzyme activities at very high dosage.
Mutagenicity studies of some of these beta-adrenergic blocking agents, 
using the Ames* bacterial and mammalian micronucleus tests, indicated 
that none of these agents give rise to significant and dose-dependent 
increases in mutations. The numbers of His+ revertant colonies produced 
with or without rat S-9 activation system and the number of micronucleated 
polychromatic cells formed in mice were not significantly increased over 
the spontaneous control levels.
Because of a suggestion that practolol toxicity, namely, ulceration of 
intestinal, nasal and oral mucosae, and the conjunctiva of the eyes may 
involve inhibition of mucus synthesis, the efects of several beta- 
adrenergic blocking agents were studied. Only practolol significantly 
inhibited mucus glycoprotein synthesis as measured by the rates of 
incorporation of radiolabelled amino acid and sugar precursors into rat 
gastrointestinal mucus glycoproteins. None of the other agents studied 
showed any effects similar to practolol.
It has further been suggested that some carcinogens, tumour-promoting 
agents and inhibitors of glycoprotein synthesis, preferentially stimulate 
tissue guanylate cyclase and cyclic GMP without concomitant increases in 
adenylate cyclase and cyclic AMP leading to a decrease in the ratios of 
adenylate/guanylate cyclases and C-AMP/C-GMP. None of the beta-adrenergic 
blocking drugs studied were shown to preferentially stimulate tissue 
guanylate cyclase and C-GMP. They did give rise to concomitant increases 
in tissue guanylate and adenylate cyclases and decreases in the C«AMP and 
C-GMP concentrations. However, there was no direct relationship between 
the ratios of adenylate/guanylate cyclases and C-AMP/C-GMP before and after 
treatment with the various agents.
KIrrationally held truths may be more 
harmful than reasoned errors”.
T.H. HUXLEY (1825-1895)
(Tne Coming of Age of the Origin of Species)
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CHAPTER ONE 
GENERAL INTRODUCTION
INTRODUCTION
Beta-adrenergic blocking agents are currently widely prescribed in 
clinical practice for the treatment of many forms of congenital heart 
diseases. It is estimated that over 2 million patients are being daily 
treated with propranolol (inderal) worldwide and similar numbers of 
patients are receiving other marketed beta-adrenergic blocking agents 
when they are considered together. Furthermore, since its introduction 
onto the market in 1965* there have been approaching 13 million patient 
years of experience with propranolol. There are about eleven beta- 
adrenergic blocking agents now available in the U.K.
Pronethalol was the first beta-blocking agent synthesized (Black and 
Stephenson, 1962) to be introduced into clinical practice. However it 
was found to produce thymic tumours in certain strains of mice (Paget, 1963? 
Alcock and Bond, 1964; Howe, 1965) and was subsequently withdrawn from 
further clinical investigations. Propranolol was introduced (Black et al, 1964 
with a more potent beta-blockade effect and used successfully in the 
treatment of angina pectoris (Gillaa and Pritchard, 1966).
The concept ofoc- and^-adrenergic receptors was first introduced by 
Ahlquist (1948) and confirmed by Moran and Perkins (1958). This finding 
, led to the introduction of the termsoC- and adrenergic blocking agents.
A beta-adrenergic blocking agent was defined by Fitzgerald and Barrett (1967) 
as a substance which competitively antagonises the effects of exogenous 
adrenaline and isoprenaline as well as antagonising stimulation of the 
cardiac sympathetic nerves and does not antagonise the effects of digitalis, 
calcium, aminophyline, acetylcholine, 5-hydroxytryptamine or histamine.
However, recent study by Preiksaitis and Kunos (1979) has demonstrated an
interconversion between oG-and -adrenergic receptors which is 
temperature dependent. The existence of two forms of ^-adrenoceptors, / 
namely and p has been demonstrated by Lands et al (1966, 1967)*
The former (^) is present in the heart muscle and the latter ((^) in 
the smooth muscle. Propranolol was found to block both adrenoceptors 
and it therefore became necessary to develop new compounds that will 
be specific to ^-adrenoceptors for use by patients with other conditions 
such as asthma (lungs possess j^-adrenoceptors)•
Practolol was the first specific^-adrenergic blocking agent to be 
developed (Dunlop and Shanks, 1968) and was later introduced into clinical 
practice. Practolol was first marketed in 1970, and by the end of 1975 
the full extent of its toxic side-effects (oculomucocutaneous syndrone) 
had become apparent. At this time it had had some 300,000 patient years 
of use in the U.K. and around 1 million worldwide. It was later withdrawn 
from the market, generally, leading to the development of new ^ -specific 
adrenergic blocking agents such as atenolol, acebutolol and metoprolol, 
whose cardioselectivity has been described in animal experiments (Barrett 
et al, 1973, Basil et al, 1973, Ablad et al, 1973*).
The dose-response relationships between beta-adrenergic blocking agents 
and beta-adrenoceptors is tissue and species dependent. In normal men 
an oral dose of practolol 1 .5 mg/kg selectively blocks the ^ -adrenoceptors 
but a dose of 12 mg/kg blocks $ -adrenoceptors as well (Lertora et al, 1975)* 
Acebutolol has been found to be cardioselective in dogs but not in man 
(Briant et aj., 1971; Basil et al, 1971? Cuthbert and Owusu-Ankomah, 1971)*
Beta-adrenergic blocking agents differ in four respects according to their 
potencies, presence or absence of membrane-stabilizing activity (MSA), 
intrinsic sympathomimetic activity (ISA) and cardioselectivity (waal- 
Manning, 1976b). Current evidence suggests, however, that relative 
differences in potency, cardioselectivity, ISA and MSA are probably of
little significance in determining the antihypertensive effectiveness of 
the various beta-adrenergic blocking agents (Hansson and Werko, 1977;
Niarchos and Tarazi, 1976; Niess and Shand, 1975)* Inspite of known 
differences in pharmacological activity, most of the drugs seem to induce 
similar antihypertensive responses if administered in appropriate doses. 
Moreover, patients who fail to respond to one beta-adrenergic blocking 
agent generally fail to respond to the others (waal-Manning, 1976a; Morgan 
et al, 1974; Doyle, 1974).
These agents represent an important therapeutic advance. Their widest 
use is in hypertension (Morgan et al, 1975; Skrabal et al, 1976) and 
ischaemic heart diseases such as angina pectoris (Pritchard, 1977)* They 
have been used in arrhythmias (Pritchard jet al, 1976; Gibson, 1974) phae- 
chromocytoma and certain forms of congenital heart diseases; myocardial 
infarction (Mueller et al, 1974). Beta-adrenergic blocking agents have 
also been assessed with varying degrees of benefit in a number of other 
conditions such as thyrotoxicosis (Schelling et al, 1973; Turner and Hill,
1968), anxiety states with somatic manifestations (Granville-Grossmann 
and Turner, 1966; Tyrer and Lader, 1974; Bonn et al, 1972), psychosis and 
schizophrenia (Bonn and Turner, 1971; Bainbridge and Greenwood, 1971; 
Veinstock and Schechter, 1975; Green and Grahame-Saith, 1976; Middlemiss 
et al, 1977), migraine (Packard, 1975), hyperthyroidism (Turner, 1974; 
Disteller et al, 1973; Murchison et al, 1976; Vartofsky et al, 1975; Goulding 
et al, 1976) and drug addiction withdrawal syndrone.
The choice of beta-adrenergic blocking agent for clinical use depends 
on their unwanted effects, ease of dosage and cost. In a patient liable 
to asthma a cardioselective drug; i.e. atenolol, diacetolol (active 
metabolite of acebutolol) ,-metoprolol and practolol tend to be, used *
Patients on agents showing symptoms of CNS disturbances i.e. vivid dreams,
can try sotalol, atenolol and nadolol (have lower lipid-solubility)•
However in most circumstances propranolol remains the choice of drug 
since it is cheap and its long-term risks are clearly understood.
Structure-Activity Relationship
For a drug to act as an antagonist of f>-adrenoceptor agonist (adrenaline 
or isoprenaline .) it must have a structure similar to that of the agonist 
in order to compete for the receptor sites. The activity of a ^-adrenergic 
blocking agent is dependent on three main structural factors.
Substituent on the amino group and oc-carbon atom
There is a clear cut structural relationship between the p>-adrenergic 
drug, isoprenallne > and the various j?>-adrenergic blocking agents (Figure 
1.1). The influence of variations in the N-alkyl substituent in 
^-adrenergic blocking agents has been intensively studied and there is 
a clear correlation between £>-adrenergic agonist and ^-adrenergic blocking 
agent. This especially holds for the change from hydrogen via the methyl 
to the isopropyl and tertiary butyl substituted derivatives. For the 
aryl substituted compounds, the relations are less clear; however, 
only a few examples have been studied.
A second structural variation is the introduction of alkyl substituents 
on the carbon atom next to the amino group, the °C-carbon. This substitution 
on theoC-carbon atom of isoprenaline ' and related potent -adrenergic 
compounds is of importance (Lands and Tainter, 1953; Triggle, 19&5; Barlow, 
1964). OC-methyl groups seem to be less compatible with ^-adrenergic 
activity than thecC-ethyl groups; larger groups are not tolerated.«C-raethyl 
substitution leads to a decrease in the activity (Corrodi et al, 1963).
The introduction of the°C-ethyl group in DCI has about the some influence 
as thecC-methyl group (Corrodi et al, 1963).
Sterical configuration
This involves the sterical configuration of the carbon atom in the side 
chain bearing the OH-group. Also the compounds devoid of this OH group 
can be considered in this respect. High ratios are reported for the 
activities of the sterical isomers of various ^ -adrenergic activity 
(Ariens, 1963). The ratio of the activities of the sterical isomers of 
various ^-adrenergic blocking agents which differ in the configuration of 
the carbon atom in the side-chain bearing the OH-group have been studied 
and as a rule large ratios are reported for the activities of the isomers 
(Bums et al, 1964; Bums and Salvador, 1967? Salvador et al, 1964; Levy, 
1964; Kvara et al, 1965; Howe, 1963)* Where the absolute configurations 
of the p>-adrenergic blocking agents have been studied, the R-isomers are 
found to have the highest activity (Howe, 1963)* This strong dependency 
of the fi-adrenergic blocking activity on the steric structure, which is 
comparable to that observed for the f>-adrenergic activity, holds for 
the effects induced by these compounds on the ^-receptors.
Catecholamine nucleus structure
Gradual elimination of the phenolic OH-groups of catecholamines shows 
that the raeta-OH group is more important than the para-OH group for the 
action both on theoC- and ^-receptors. (Ariens, 1963; Corrodi et al, 1963; 
Bovet and Bovet-Nitti, 1948; Triggle, 1965). Elimination of both OH-groups 
results in a decrease in the intrinsic activity on the f>-adrenergic 
receptors. The resulting phenylethanolamine act as weak ^-adrenergic 
blocking agents. For instance, phenylethanolamine and its N-methyl and 
its N-isopropyl derivatives have a ^-adrenergic blocking activity with 
respect to the tachycardia induced by ^-adrenergic drugs (Ariens, 1963;
Pratesi and Grana, I967). Introduction of a halogen especially a chlorine 
atom or of a methyl group in the raeta and/or para position results in an 
increase in the affinity of the ^-adrenergic blocking agents to their
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receptors as mentioned, (Powell and Slater, 1958; Pratesi and Grana, 1967? 
Corrodi et al, 1963)* Larger alkyl groups, such as ethyl groups, are found 
to be less suitable (Corrodi et al» 1963)*
The structure-activity relationship outlined indicates that the chemical 
properties of the substituent on the nucleus are of primary importance for 
the intrinsic activity on the f>-receptors. An interesting aspect of the 
structure-activity relationship, is the substitution of a phenolic 0H- 
group by a methylsulphonamide group. This group behaves to a certain 
degree as a bio-isoteric group for the phenolic OH-group (Staton et al, 
1965b; Larsen and Lish, 1964; Oloth et ad, 1966), Some of the compounds 
with a para- or inter-methylsulphonamide group act as p>-adrenergic or 
p>-adrenergic blocking agents (Lish et al, 1965? Kvam et al, 1965; Staton , 
et al, 1965a,b; Dungan et al, I965K
Pharmacokinetics of Beta-adrenergic Blocking Agents
The pharmacokinetics of most ^-adrenergic blocking agents have been 
extensively studied with respect to their absorption and mode of 
elimination, bioavailability, drug clearance and plasma half-life, 
metabolism and tissue distribution.
Absorption and mode of elimination
All the beta-adrenergic blocking agents with the possible exception of
acebutolol and atenolol are well absorbed from the alimentary tract (GIT)
following oral administration (Shand, 1974) as shown in Table 1,1, Peak
plasma levels generally occur within 1-3 hours. The absorption of sustained
release preparations of alprenolol and oxprenolol is more prolonged, and
lover peak levels are achieved (Johansson et al, 1971)• In man, the
absorption of atenolol after oral administration is incomplete, but blood
levels after oral administration is incomplete, but blood levels after lOOmg 
dose are consistent and adequate (Graham e_t al, 1973, Kaye et al, 1976).
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entirely by hepatic metabolism (Paterson et al, 1970; Johansson et al, 
1971; Reiss et al, 1970; Bodem et al, 1976). Practolol and Atenolol are 
eliminated almost completely by renal mechanisms, largely as a function 
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Figure 1.2 Clearance of (^-adrenergic blockers Meier et al, 1977
of glomerular filtration (Bodem and Chidsey, 19735 Bodem et al, 1976;
Baker et al, 1974)• Sotalol and acebutolol are mainly eliminated by 
renal mechanisms but metabolized to a lesser extent in the liver whereas 
timolol and pindolol are mainly metabolized by the liver and eliminated 
to a lesser extent by renal mechanisms, (Ohnhaus, 1973» Shand, 1974;
Johnsson and Ragardh, 1976; waal-Manning, 1976a)* The clearance of some 
beta-adrenergic blocking agents by the liver and kidneys is shown in 
Figure 1.2.
Bioavailability
With some drugs which are extensively metabolized by the liver, some of 
the administered dose fails to reach the circulation after oral administra­
tion, despite complete alimentary absorption, because the drug in the portal 
vein is taken up and removed by the liver before it can appear in the
systemic circulation, (Gibaldi et al, 1972). This presystemic hepetic eliraina- 
tion is referred to as "first-pass" effect. It is negligible in the case of
practolol and pindolol and about 60% for propranolol, 90% t o r alprenolol,
50% for raetoprolol and 30-50% t o r oxprenolol (Table 1.1). Hie relationship 
between bioavailability and oral dose is therefore not proportional; the 
availability of small doses being very low. As the dose increases, 
proportionately more drug reaches the systemic circulation. This kinetic 
situation applies to the disposition not only of propranolol and alprenolol 
(Shand, 1974; Johnsson and Ragardh, 1976) but probably also to oxprenolol, 
(Riess et al, 1974).
Drug clearance and plasma half-life
The drug clearance of various £>-adrenergic blocking agents vary between 
0.14 - 1.2 litres/rain. Because of the very efficient removal by metabolism, 
the half-life of these drugs in the plasma is short (2-3 hours).despite their 
large volume of distribution, (Shand and Ragno, 1972; Johansson ejt al, 1971)* 
Pindolol, however has a longer half-life of 3-4 hours because of its smaller 
volume of distribution (Hicks et al, 1972). Since practolol is eliminated 
differently from the other beta-adrenergic blocking agents, it is cleared 
less rapidly, at a rate approximating that of glomerular filtration and its 
half-life (9-12 hours) is much longer than that of other beta-adrenergic 
blockers (Bodea and Chidsey, 1973? Reeves et al, 1978). The half-life of 
atenolol is about 6 hours (Brown et al, 1976).
The duration of effect of ^ -adrenergic blocking agents is different from 
the plasma half-life. Although most ^-adrenergic blocking agents have a 
relatively short plasma half-life, their duration of ^-blocking or anti­
hypertensive effect is relatively long lasting. Most compounds can there­
fore be given at much longer dose intervals than indicated by their plasma 
half-lives (Johnsson and Regardh, 1976). Above certain dosage levels, increas­
ing the size of the dose leads to greater duration of effect, rather than a 
greater magnitude of response (Carruthers et al, 1973)*
A correlation between the plasma level and therapeutic effect has been 
demonstrated for alprenolol (Collate et al, 1976), propranolol (Cleaveland 
and Shand, 1971)» sotalol (Sundquist et al, 1974) and pindolol (Anavakar 
et al, 1975? waal-Manning, 1976a), but studies thus far have failed to 
demonstrates significant correlation for metoprolol (Bengstsson et al, 
1974), oxprenolol (Brunner et al, 1975) practolol (Sundquist et al, 
1974). The difference in the time-course between the anti-hypertensive 
effect and the plasma level means that for most beta-adrenergic blocking 
agents, a twice daily (or in some cases once daily) dosage regimen can 
be used.
Tissue distribution
With the exception of sotalol, which shows a higher distribution in the 
peripheral tissues than the CNS, the other p>-adrenergic blocking agents 
show the reverse distribution pattern (Scales and Cosgrove, 1970? Garvey 
and Ram, 1975? Hayes and Copper, 1971)*
The higher ratios obtained with propranolol and alprenolol compared to 
practolol with regard to brain/blood, lung/blood and heart/blood levels 
are probably related to the low solubility of practolol compared to 
propranolol and alprenolol, and this may have a bearing on the cardio­
selectivity of practolol. However, it is likely that all beta-adrenergic 
blocking agents enter the CNS to some degree. (Scales and Cosgrove, 1970; 
Johnsson and Regardh, 1976).
Metabolism
The metabolism of most ^-adrenergic blocking agents have been extensively 
studied and some of the metabolites have been isolated and identified 
(Bond, 1967? Scales and Cosgrove, 1970, Bond and Howe, 1967? Hayes and 
Copper, 1971? Leinweber et al, 1971)* However the biological significance 
of these metabolites have not been fully investigated.
N H C O C H C H
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OCH CHOHCH NHCH(CH )
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Figure 1.3 Pathway of metabolism of acebutolol
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Figure 1.4 Metabolic pathway of atenolol
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Figure 1.7 Metabolic pathway of practolol
Pronethalol is metabolized by two main pathways; side chain oxidation 
and ring hydroxylation and conjugation* Five metabolites have been 
identified, four being formed by degradation and oxidation of the 
isopropylaminoethanol side chain* The fifth metabolite, 7-hydroxy- 
analogue of pronethalol is partly present in the free form, but the 
major amount is present as the glucuronide (Bond and Howe, 1967)* Howe 
(1965) proposed a probable production of an ethyleneimine derivative, 
although it has not been identified either as a minor or transient 
metabolite, of pronethalol as the proximate carcinogen responsible for 
its tumorigenic properties*
Propranolol undergoes similar modes of metabolism as for pronethalol*
Two major metabolites were initially detected and the major pathway of 
excretion is the urine* The first metabolite is a product of oxidation 
of the side chain* The second is the hydroxylated derivative of propranolol 
which also exists in its glucuronide form (Bond, 1967)* Recent human 
studies have however led to the identification, in urine, of O-methylated 
catechol-like metabolites (Valle e£ al, 1978)*
The major metabolite of practolol accounts for 9% of the dose and has 
been identified as the hydroxylated derivative* One-third of this is 
excreted as the free compound and the remainder as a glucuronide conjugate* 
About 4% of the drug is metabolized by the removal of the acetyl side- 
chain thought to be responsible for its adverse side-effects, and 80-90% 
remain unchanged in the urine of dogs, rats and mice (Scales and Cosgrove, 
1970)* Recent metabolic studies in man has demonstrated that the major 
metabolites were 3a~bydroxy and desacetyl practolol* Desacetylation is 
however a minor metabolic pathway representing 5% o f the drug* 3-i3% 
is metabolized and eliminated in the urine and about the same amount 
remained unchanged in animal studies*
Atenolol undergoes a 10$ metabolism leading to the formation of hydroxy 
derivative and its glucuronide conjugate.40 - 50$ of the unchanged 
compound is recovered in the urine (Brown et al, 1976).
The major metabolite of acebutolol is one in which the ethyl group of the 
side chain para to the isopropylamino-ethanol side chain has been removed 
(Steyn, 1976). Recent study by Andersen and Davis (1979) k&s led to the 
identification in human urine, a new metabolite which correlates to that 
found in the rat.
The metabolic pathways of the five main beta-adrenergic blocking agents 
used in the present study and described above are shown in Figures 1*3 •
1.8.
The Microsomal Drug-metabolizing Enzyme System
The most important of the hepatic drug-metabolizing enzyme# are the aixed- 
function oxidases which oxygenate drugs and are complex, multicomponent 
systems comprising NADPH , a phospholipid-protohaeme-sulphite protein 
complex known as cytochrome P-450 and a linking electron transport system 
of cytochrome P-450 reductase, NADPH cytochrome c reductase and possiblydt
cytochrome b^ _ (Coon et al, 1973; Estabrook et al, 1973)* The mechanism of 
oxygenation (hydroxylation) of drugs and xenobiotics is postulated in 
Figure 1.8. The mixed-function oxidases of the endoplasmic reticulum of 
the liver and of certain other tissues reticulum of the liver and of certain 
other tissues such as the gastrointestinal mucosa, the lungs and skin 
catalyse these bydroxylation reactions.
The hydroxylations catalysed by this system are frequently referred to as 
non-specific reactions, whereas infact these enzymes show a remarkably 
high degree of specificity of the substrate and of the insertion of the 
oxygen. These enzymes are very versatile and are able to carry out 
oxygenation of a number of different substrates. This is made possible
by the presence of different types of cytochrome P-450, by conformational 
changes of this enzyme system which converts cytochrome P-450 to cytochrome 
P-448 and also by alternative methods of oxygen transfer (Stier, 1976). 
Oxygen may be inserted into the substrate when this is firmly bound to the 
substrate-specific protein of cytochrome P-450 in the proximity of the 
haem moiety, or alternatively a labile, metastable oxygenated species 
such as the superoxy anion or radical may be generated by this system 
which subsequently hydroxylates the substrate possibly without its binding 
to the active site of the cytochrome P-450 enzyme. A number of these drug 
hydroxylations are inhibited by the enzyme superoxide dismutase, which 
destroys the superoxide anion (Parke, 1978).
Cytochrome P-450 has been demonstrated in many organisms including fish 
(Chambers and Yarbrough, 1976), birds (Yawetz et al, 1968), insects 
(Wilkinson and Brattsten, 1972), yeast (Wiseman et al, 1975) and bacteria 
(Sato et al, 1973)* In its oxidized form, the haemoprotein combines with 
foreign compounds, as well as endogenous substrates, to produce difference 
spectra of two general types, type I and type 33.. The type I spectrum has 
a peak at 385nm and a trough at 420ms, while type II has a peak at about 
430nm and a trough at about 395nm (Reramer jet al, 1966; Imai and Sato, 1966; 
Schenkman et al, 1967). In addition, a modified type EC or reverse type I 
(4l5nm to 420nm peak, 390nra trough) spectral change has been demonstrated.
The affinity of binding of substrates to cytochrome P-450 can be estimated 
by measurement of the spectral constant (Ks). The Ks value, by definition, 
is the concentration of substrate required for half maximal spectrum 
development. Some workers found a good correlation between Ks value for 
binding and the Km value for metabolism of type I compounds, such as 
hexobarbitone and aminopyrine (Schenkman et al, 1967; Remmer et al, 1969)* 
However, in general, these two values are not directly correlated 
(Mannering, 1971)*
Type I compounds do not interact directly with the haem of cytochrome 
P-450 but reaction with a hydrocarbon residue of the apoprotein occurs 
(Yoshida and Kumaoka, 1975)* Therefore, the extraction of phospholipids 
destroys the type I interaction (Leibman and Estabrook, 1971; Chaplin and 
Mannering, 1970)# The reverse type I spectral change results from the 
displacement of an endogenous type I substrate from the oxidized enzyme 
(Turner et al, 1977) by the presence of a compound with a hydroxyl group, 
e.g. an alcohol (Yoshida and Kumaoka, 1975)*
Compounds, which contain a basic amino group, induce the type HI spectral 
change by interacting directly with the haem iron of the cytochrome 
(Yoshida and Kumaoka, 1975)* Type XI compounds also include compounds 
with oxygen or sulphur atoms containing a pair of non-bonded electrons.
Cytochrome P-450, in its reduced form, similarly interacts with ethyl 
isocyanide and characteristically has Soret peaks at 430nm and 455n®
(imai and Sato, 1966). The relative sizes of the two peaks are pH 
dependent, but the sum of the heights are about the same regardless of 
pH. Changes in the pH equilibrium point at which the peaks are of equal 
magnitude have been used in studies of the qualitative differences of 
cytochrome P-450 in microsomes from untreated and 3-®ethylcholanthrene- 
treated rats (Sladek and Mannering, 1966).
Nature of hepatic microsomal enzyme inducers
The drugs and foreign compoundswhich induce the microsomal enzymes have 
widely differing pharmacological activities, e.g. phenobarbital (hypnotic), 
butylated hydroxytoluene (BHT, food anti-oxidant), DDT (pesticide), 
3-methylcholanthrene (carcinogen), and the only features they seem to hare 
in common are:
a) Lipid-soluble and hence become localized in the endoplasmic reticulum
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of the liver.
b) Substrates of or become bound to the microsomal drug-metabolizing 
enzymes.
The latter appears to be an important criterion for the microsomal enzyme 
induction, at least at the translational level. Study of the inductive 
effects of a series of barbiturate drugs on rat hepatic microsomal enzymes, 
showed an inverse correlation between the rates of metabolism of the 
barbiturates as determined by their plasma half-lives and the extent of 
induction that they produced (Ioannides, 1973)* It is reasonable there­
fore to infer that the longer the substrate remains in the body and hence 
in contact with the enzyme, the greater will be the extent of induction, 
and indeed this is substantiated by the high level of induction that 
results with the methylenedioxyaryl compounds such as safrole and 
piperonyl butoxide which form stable ligand complexes with cytochrome 
P-450 (Parke and Hahman, 1970; Philpot and Hodgson, 1971)*
The phenomenon of induction of the microsomal drug-metabolizing enzymes 
would thus appear to be an example of substrate-mediated enzyme induction 
where because of the unique multifunctional nature of the enzyme system 
involved, one substrate is able to increase not only the enzymic activity 
required for its own metabolism but also that for many others. Many 
naturally occuring anutrients e.g. terpenes, couraarins, flavones and 
caffeine have been shown to stimulate the hepatic drug-metabolizing 
enzymes thus confirming the fundamental nature of anutrients as natural 
substrates of these enzymes'
Forms of cytochrome P-450
Administration of 3-®ethylcholanthrene to normal rats led to the produc­
tion of a P-450 haemoprotein which differed from that found in untreated 
animals (Sladek and Mannering, 19&6). This new haemoprotein, in its
reduced fora combined with CO had a maximum absorption at 448 nm instead 
of 450nra (Alvarese t jlI, 1967). Its binding to ethyl isocyanide also 
differed in that the peak size at 455n® was specifically increased 
whilst the 430run peak remained relatively unaltered; also on the basis 
of the pH dependency of the ethyl isocyanide interacton, it was concluded 
that a new haemoprotein (cytochrome P-448) was formed (Mannering jet al,
1969)• Further studies, confirmed the existence of the new cytochrome 
by virtue of its spectral binding characteristics with various types of 
substrates (Hildebrandt et al, 1968; Remmer jet al, 19&9; Mannering, 1971) 
and its preferential specificity towards the metabolism of different 
substrates (Conney etj al, 19&9; Kuntzman et al, 1969)* When animals are 
treated with phenobarbitone, cytochrome P-450 concentrations is greatly 
increased but remains qualitatively similar to that found in untreated 
animals.
Cytochrome P-450 from rats pretreated with phenobarbitone and cytochrome 
P-448 from rats pretreated with 3-»ethylcholanthrene have been solubilized 
from liver microsomes treated with sodium cholate and fractionated by 
ammonium sulphate, calcium phosphate gel and column chromatography on 
D£A£-cellulose with a further purification on a CM-cellulose column (Lu 
e^ t jal, 1976). Hie two h&emoproteins were shown to have different 
molecular weight and different spectral, immunological and catalytic 
properties. This is consistent with the view that cytochrome P-450 
in liver microsomes prepared from animals induced with drugs is different 
from that induced by polycyclic hydrocarbons.
The lack of substrate specificity of the microsomal mixed-function 
oxidase system has led to the suspicion that more than a single species 
of cytochrome P-450 may exist in the system. One of the advantages of 
the presence of several enzymes with a certain degree of specificity is 
that low levels of toxic environmental compounds may efficiently be
removed from the body. Also, the synthesis of an enzyme effective 
in the metabolism of a particular drug is biologically more economical 
than to continuously synthesize large amounts of a less efficient enzyme 
(Ullrich, 1977).
Recently, several workers have identified more than one form of cytochrome 
P-450 in liver microsomal preparations of untreated animals (Comai and 
Gaylor, 1973? Haugen et al, 1975a? Philpot and Arinc, 1976). Gibson and 
Schenkman (1978) obtained two forms of cytochrome P-450 (I and U )  from 
liver microsomes of untreated rats by lauric acid affinity chromatography, 
with further purification by gel filtration giving an overall 50% yield 
of the haemoprotein. Marked differences in substrate specificities of 
the two fractions were observed; for example, high activity of cytochrome 
P-450 H  towards the metabolism of ethylmorphine was obtained but cytochrome 
P-450 I could only poorly metabolize this compound. Their CO difference 
spectral maxima also differed in that cytochrome P-450 I had its peak 
between 449*5nm and 451nra whilst cytochrome P-450 IX absorbed maximally 
between 448.5nm and 450nm. Hie two haemoprotein also responded differently 
towards destruction by linoleic acid hydroperoxide.
Multiple forms of cytochrome P-450 have similarly been demonstrated in
microsomal preparations from either phenobarbital or 3-ro©'tbylc60lan6hrene-
treated animals (Guengerich, 1977? Gustafsson and Ingel-Sundberg, 1976?
Thomas et al, 1976a 1976b; Ryan et al, 1975? Coon et al, 1975? Lu et al,
1976). Four distinct cytochrome P-450 fractions (A , A;, C. and C ) have
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been isolated from the liver microsomes of phenobarbital-treated mice 
(Haugen jet al_, 19756) by solubilization with sodium cholate and purification 
through several stages, including ion-exchange chromatography. All four 
fractions exhibited different absorption maxima in the reduced .CO difference 
spectrum ranging from 449nra to 451nm. Testosterone was hydroxylated in the
16 {^-position by Cj and C^, in the 16 oC-position by and y composition by
A • A and A fractions possessed high activities towards the metabolism 
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of benzpyrene whilst A^ preferentially metabolized 7-ethoxycoumarin and 
couraarin. Benzphetamine was particularly well metabolized by C^. There­
fore, the cytochrome P-450 fractions show preference towards the metabolism 
of various substrates although their substrate specificities are broad and 
overlapping (La et al^ 1975)*
The cytochrome P-450 population in liver microsomes from phenobarbital or
3-methylcholanthrene-treated rats is obviously different. Cytochrome 
P-450 preparations from different species of animals treated with the 
same inducer, however, are also different proteins although they may have 
similar catalytic specificity towards different substrates and have 
identical CO difference spectra. Thomas et jal (1976b) found that antibodies 
produced from the purified cytochrome P-448 obtained from liver microsomes 
of 3-»ethylcholanthrene-treated rats, cross-reacted poorly with cytochrome 
P-448 purified from liver microsomes of 3~reethylcholanthrene-treated rabbits.
The existence of multiple froms of cytochrome P-450 in a microsomal 
preparation may explain the species, strain, age, tissue and sex differences 
in mixed-function oxidation (Lu and West, 1978). It may also explain the 
kinetics and patterns of inhibition with different substrates,inducing 
agents and inhibitors (Haugen et al, 1975b; Ullrich and Kremers, 1977)*
Interactions of beta-adrenergic blocking agents with cytochrome P-450
The ability of the liver to bind and metabolize r,first-passM drugs is a 
major factor responsible for their blood concentrations on oral administra­
tion, Although some beta-adrenergic blocking agents undergo ’first-pass” 
metabolism, their binding to hepatic microsomal cytochrome P-450 has not 
been extensively studied.
Alprenolol has been shown to bind with high affinity to cytochrome P-450 
Siyinga type I spectral binding characteristic (Grundin et alf 1974,1975).
Propranlol has similar characteristics (Evans et al, 1973)* The 
microsomes appear to have four classes of binding capacity for alprenolol.
Its binding to, and gradual saturation of, the high affinity binding site 
of cytochrome P-450 is an important determinant of the low and dose- 
dependent availability of alprenolol in man (von Bahr et al, 1974). It 
has been suggested that not only the binding capacity but also the rate 
of oxidation catalysed by this site should be important for the ”availability 
threshold” since this rate largely governs the degree of saturation of the 
site in a metabolically functioning system (von Bahr, et al 1976).
It has been well established that compounds which bind to the active site 
of the microsomal cytochrome P-450 (type I compounds) must possess a suitable 
degree of lipophilic character to penetrate the lipid environment in which the 
microsomal enzyme is located (Ito and Sato, 1969)*
The role of lipid solubility in determining both the affinity (Ks) and the 
extent (% of P-450 involved in the binding) of interactions of a type I 
compound with liver microsomal cytochrome P-450 is still not clear (Martin 
and Hansch, 1971; Hazel et al, 1966; Jansson et al, 1972; Canady et al, 1974).
Recent studies by Pacino and Lanzani (1979) led to the observation of a 
strong correlation between the lipid solubility of some beta-adrenergic 
blocking agents and their affinity constants (Ks) for cytochrome P-450*
Other molecular properties were also found to be of great importance in 
determining the extent with which the drugs interact with cytochrome P-450. 
The kinetic constants (Km and Vmax) for the metabolism of alprenolol and 
propranolol by the rat liver microsomal monooxygenases are related 
respectively to the lipophilic character and binding affinities of the 
molecules and to the extent of cytochrome P-450 bound. The poorly 
lipophilic compounds, oxprenolol and raethypranol, bind to cytochrome 
P-450 to a greater extent than the more lipophilic propranolol and this
of the molecule facilitates the attack of these compounds on the active 
site of the cytochrome.
Microsomal chemical activation and carcinogenesis
Attention has recently been directed towards the activation of toxic
chemicals by enzymes of the endoplasmic reticulum, more especially, to
the activation of carcinogens. The carcinogenic polycyclic hydrocarbons,
benzo(a)pyrene and benz(a)anthracene, are characterized by the presence
of the phenanthrene nucleus within the chemical structure and it has been
proposed (Jerina and Daly, 1977; Jerina and Lehr, 1977) that activation of
polycyclic hydrocarbons to proximate or ultimate carcinogens necessitates
fbay region1 epoxidation of this phenanthrene nucleus. Other workers (Sims
polycyclic
et al, 1974; Swaisland et al, 1974) have found that the (_ epoxide ..is 
converted into the corresponding dihydrodiol, by epoxide hydrase, then 
further oxygenation to yield the diol epoxide. These diol epoxides do not 
appear to be suitable substrates for epoxide hydrase, and form stabilized 
internal ion-pair compounds which react as carboniura with DNA, even in the 
presence of glutathione and proteins, so that no threshold concentration of 
the diol epoxide need exist for DNA arylation and consequent damage of DNA 
and carcinogenesis (Hulbert, 1975)* Microsomal oxygenation is also known 
to be involved in the activation of carcinogenic aromatic amines such as 
2-naphthylamine (Radomski and Brill, 1970)» carcinogenic amides, such as 
2-acetamidofluorene, (Weisburger et al, 1972) and carcinogenic nitrosamines 
(Magee and Barnes, 19&7)-
Microsomal enzyme stimulation
True induction of the drug-metabolizing enzymes involves de novo protein 
synthesis, and may result from treatment of animals with drugs or certain 
carcinogens. Stimulation does not require the synthesis of more enzyme 
protein but probably results from a conformational change of the existing.
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Figure .1,9 Metabolic hydroxylation of biphenyl
enzyme, cytochrome P-450.
These differences are well illustrated by the model substrate biphenyl. 
Microsomal oxygenation of biphenyl yields two major products namely 2- 
hydroxybiphenyl and 4-hydroxybiphenyl (Figure 1.9). This is of interest 
since both 2- and 4-hydroxylatbn of biphenyl are catalysed by cytochrome- 
P-448, with cytochrome P-450 catalysing only the 4-hydroxylation (Bridges 
€st a!L, 1973? Atlas and Nebert, 1976). This specificity of the 2-hydroxylation 
by cytochrome P-448 and the known formation of cytochrome P-448 by carcinogens 
has suggested a correlation between the effect of carcinogens on the endoplasmic 
reticulum and an increase in the enzymic 2-hydroxylation of biphenyl (Creaven 
and Parke, 1966; McPherson et al, 1976). Furthermore, the irreversible 
displacement of ribosomes from the endoplasmic reticulum (Degranulation) 
by carcinogens (Williams and Rabin, 1971; Delaunay and Schapira, 1974) has 
suggested a further relationship between degranulation of the endoplasmic 
reticulum and the expression of the enzyme biphenyl 2-hydroxylase (Parke,
1977a).
The increased biphenyl 4-hydroxylase activity is the result of enzyme 
induction whereas the increase in biphenyl 2-hydroxylase activity is 
biphasic, comprising an initial stimulation phase followed later by true 
enzyme induction. The initial stimulation, which occurs within 0-15 minutes 
of treatment with the carcinogen, probably represents a conformational change 
of cytochrome P-450 to cytochrome P-448 and may occur simultaneously to 
the degranulation of the endoplasmic reticulum. The structure of biphenyl 
contains the spatial arrangement of the phenanthrene nucleus , and the
2-hydroxylation, but not the 4-hydroxylation, may be considered as fbay- 
region1 oxygenation.
Glycoprotein synthesis and malignancy
Another essential biological function of the endoplasmic reticulum is the
synthesis of glycoproteins which play a vital role in the overall 
economy of the cell and of the eukaryotic organism. Glycoproteins 
secreted into the plasma membrane glycocalyx regulate cell division, 
and glycoproteins secreted from the cell, such as immunoglobulins, play 
a major role in immune surveillance. The nature of the carbohydrate 
moieties of these glycoproteins appears to be the critical feature 
determining the rate of mitosis, the immune characteristics of the cell 
and the immune surveillance within the living organism. However, the 
mechanism by which the various glycosyl transferases within the endoplasmic 
reticulum, responsible for initiation of glycoprotein synthesis, are regulated 
is yet to be established (Schachter, 1974).
The degranulation of the endoplasmic reticulum which accompanies 
carcinogenesis (Delaunay and Schapira, 1974) must of consequence be 
accompanied by inhibition of glycoprotein synthesis (Parke 1977b). Indeed 
in malignantly transformed cells, one of the earliest changes observed 
is the loss of a high molecular weight glycoprotein from the cell surface 
(Warren jat al, 1974) and changes in the nature of the terminal sugar 
moieties of the glycoproteins of the glycocalyx. Elevated levels of 
certain glycosyltransferases have been observed in the plasma of cancer 
patients, and high levels of fucosyltransferase with correspondingly 
low levels of sialyltransferase and galactosyltransferase were demonstrated 
in various human metastasizing tumours (Kessel et al, 1977)* A marked 
inhibition of glycosyltransferase in the synthesis of gastric mucus in 
patients with gastric carcinoma has been observed (Parke and Symons, 1977)*
It appears that both the quantitative and qualitative aspects of glycoprotein 
synthesis are profoundly affected by malignant transformation, and that 
the changes occuring in the glycoprotein of the cell surface are associated 
with many of the characteristics of malignant cell, namely, loss of 
adhesiveness, accelerated cell division and altered antigenicity
(Warren et al, 1974). Furthermore, degranulation of the endoplasmic 
reticulum might lead to increased synthesis of intracellular proteins 
by the cytoplasmic ribosomes which, as in the neonate, would lead to 
the growth of the cell and accelerated cell division. Hence, degranulation 
would result in a switchover of the economy of the cell from a predominance 
of synthesis of glycoproteins for export (mucus, immunoglobulins, serum 
albumin) to the neonatal state of predominantly intracellular protein 
synthesis, with accelerated cell growth and mitosis.
Cyclic Nucleotides and Malignancy
It has been suggested that many of the properties of malignantly transformed 
cells are due to low levels of cyclic AMP (Pastan et al, 1975)• When 
transformed isolated cells or hepatoma cells in culture are treated with 
cyclic AMP, the transformed cells change in appearance to more closely 
resemble normal cells and grow more slowly (Pastan, 1975; van Wijk et al,
1972). On the other hand, dibutyryl cyclic AMP has been shown to increase 
the frequency of cell transformation by oncogenic viruses (Smith et al,
1973)) and chemical carcinogenesis is associated with an increased 
responsiveness of adenylate cyclase to hormonal control (Boyd et al, 1974), 
so that a cascade effect magnifying the malignant transformation could 
result especially in stressful conditions when the circulating catecholamines 
are high (Figure 1.10). Although the level of cyclic AMP of established 
tumours is always low and the hormonal responsiveness of their adenylate 
cyclase is not high (Boyd et al, 1974) increased levels of cyclic AMP are 
characteristic of the initial malignant cell transformation. In keeping with 
this hypothesis is the observation that the tumour-promoting phorbol esters, 
applied to mouse epidermis also produce an initial increase in cyclic AMP 
followed by a marked depression, then a second period of elevation (Grimm and 
Marks, 1974). At the same time the hormonal regulation of adenylate cyclase
is largely lost, indicating that the tumour promoters have resulted in
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Figure 1*10 Possible Cascade Effect of Chemical Carcinogens and 
Cyclic AMP in Malignant Cell Transformation
damage of the cell membrane , the site of the ^-adrenergic receptor of 
adenylate cyclase.
Recent work has suggested that the regulation of DNA synthesis and cell 
division is controlled by the ratio of cyclic AMP to cyclic GMP rather 
than by cyclic AMP alone. The tumour-promoting phorbol esters result in 
a marked increase in cyclic GMP, and conversely, cyclic AMP reduces the 
promoting effects of the phorbol esters. An increase of DNA synthesis 
which follows a reduction of the cyclic AMP/cyclic GMP ratio, is considered 
to be the most important effect of the phorbol ester promoters, rather 
than inhibition of DNA repair mechanisms (Trosko et al, 1975)*
Toxicity of Beta-adrenergic Blocking Agents
J
The toxicological effects of these agents is reflected in their adverse 
drug reactions and potential carcinogenicity.
Adverse-reaction of beta-adrenergic blocking agents
A characteristic immune reaction - the oculomucocutaneous syndrome,
affecting singly or in combination,eyes, raucous and serous membranes * and 
the skin, often in association with positive antinuclear factor (ANF) - 
has been reported in practolol-treated patients (Wright, 1975? vaal-M&nning, 
1975? Brown et jal, 197^? Zacharais, 1972; Felix et al, 197^? Curaberbatch, 
Padfield et al, 1975? Knapp and Galloway, 1975)*
Many of the practolol reactions are reversible on withdrawal of the drug 
together with topical corticosteroids, artificial tear solutions, anti­
biotic eye drops and oral corticosteroids* Polyserositis and fibrosing 
peritonitis may however progress inspite of withdrawal of the drug and 
have developed up to a year after discontinuation of practolol (Ratfrey 
and Denman, 1973? Rowland and Stevenson, 1972; Felix et al, 1975? Lloyll, 
1975? Holt and Vaddington, 1975? Wright, 1975? Nicholls, 1976).
It is not known whether the practolol reaction is specific for practolol 
or is the direct specific result of pharmacologically induced change by 
^-blockade (Gaylarde and Sarkany, 1975)* There have been few convincing 
reports of the oculomucocut&neous reactions with oxprenolol (Holt and 
Waddington, 1975? Knapp et al, 1975) and one with propranolol (Cubey and 
Taylor, 1975)
The cause and mechanism of this adverse reaction of practolol has yet 
to be classified. It was earlier suggested that it may be due to the 
differences in metabolism amongst various individuals and possibly the 
long plasma half-life. However, recent studies by Reeves et al, (1978) 
led to the suggestion that the adverse re a c tio n s associated with practolol 
may be unrelated to metabolisra or kinetics.
Two separate processes have been suggested for the lachrymal gland and 
conjunctival damage (Wright, 1975)* Firstly, the drug may accumulate 
locally in the lachrymal tissue and may have a local toxic effect on
secreting cells. Secondly, it is likely that the conjunctiva is damaged 
by an antibody identified by Amos et al, (1975) as antinuclear antibody 
(ANA), which binds to the intracellular region of the squamous epithelial 
tissue. Mackie et ajL, (1977) have suggested that the dry eye observed in 
patients on beta-adrenergic blocking agents, particularly ^ -selective 
blocker, is indicative of a reduction in tear lysozyme formation 
suggesting an impaired lachrymal gland function.
Brenner et al, (1968) have shown that P>-adrenergic blockade increases 
antibody formation in response to antigen challenge and that adrenaline 
suppresses the normal response to antigenic stimulation. Furthermore, 
^-adrenergic blockers interfere with the action of anti-inflammatory agents 
(Reesterer and Jaques, 1968) and propranolol prevents the response of 
lymphocytes to phytohaemagglutinin in vitro (Smith et al, 1971)* Finally 
adrenaline activates epidermal adenylate cyclase activity and reduces 
epidermal cell division (Yoshikawa et al, 1975)• P>-adrenergic blockers 
antagonize this effect; suppressing cyclic AMP formation and encouraging 
cell division and probably predispose to the development of psoriasiform 
changes in the skin.
It has however been suggested by Ratfrey and Denman (1973) that since 
practolol acts as a partial agonist it will stimulate cyclic AMP synthesis. 
This in turn may have some direct effect on epidermal cells or impair the 
activity of T-lymphocytes populaton; resulting in the production of 
lymphocytes with autoimmune propensities.
Carcinogenicity potential of beta-adrenergic blocking agents
Pronethalol, the first [?>-adrenergic blocking agent to be put to clinical 
test, was reported to induce tumours of the lymphoreticular system in certain
strains of mice, after oral administration of 200 mg/kg for a period of
2-3 months, whereas long-term administration up to 2 years to rats and 
guinea-pigs failed to elicit any evidence of carcinogenicity (Paget, 1963;
A1cock and Bond, 1964; Howe, 1965)•
Practolol and alprenolol have been shown to give some indications of 
tumorigenicity in rodents. In addition a variety of other p>-adrenergic 
blocking agents have proved to be tumorigenic or otherwise hazardous. Two 
cardioselective agents, pamatolol and talomolol, have produced carcinomas 
of the liver in rats and talomolol has produced mammary carcinomas in mice 
as well. Other drugs of this general class appear to have producedbenign 
tumours although some of the results are equivocal, necessitating repeat 
studies (FDA report, Drug Bulletin, 1978).
Newbeme et al, (1977) investigated the carcinogenicity potentials of 
oxprenolol and pronethalol in mice and rats and showed that neither compounds 
have any indications of tumour formation after an 18-21 month study at dose 
levels of 15, 50 and 1^0 mg/kg. These findings are at variance with those 
reported for pronethalol (Paget, 19635. Alcock and Bond, 1964; Howe, 1965)*
In attempting to clarify the disparity in response to pronethalol between 
the mouse and other species, Howe (1965) proposed a probable production 
of an ethyleneimine derivate of pronethalol which might be the proximate 
carcinogen of pronethalol in vivo in the mouse, although an ethyleneimine 
structure has not been identified as either a minor or transient metabolite 
of pronethalol.
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Recent studies on the potential carcinogenicity/propranolol have cast 
doubts as to its safety. Propranolol administered in drinking water during 
treatment vdth a fixed concentration of the carcinogen 3-methyl-4- 
diraethylaminoazobenzene, for a period of 14-20 weeks, produced dose-
dependent increases in the incidence of tumours in rat livers (Boyd and 
Martin, 1977)- However, it is not clear whether this effect of 
propranolol was due to specific beta-blockade or to non-specific actions.
Nor is it clear whether this effect is due to direct action on the liver 
cells or to an effect on appetite (to alter intake of carcinogen) or on 
the immune system. Further studies with propranolol in mice administered 
with the drug, at low doses of about 0.7 «g/kg for 2-8 months, showed time- 
related changes in the salivary glands with epithelial necrosis and 
lymphocyte infiltration and the appearance of granulomas on the serosal 
surface of the colon and duodenum (Smith and Butler, 1978)
In a study of the carcinogenesis of sotalol hydrochloride which included 
propranolol, Viekel and Kelly (1979) showed that propranolol administered 
to mice and rats in their diets, at daily dose levels of 100 and 37*5 rag/&9 
respectively for a period of 78 weeks, did not produce any changes in types 
and frequency of tumours as compared to control in either species. Sotalol 
hydrochloride administered to both species in their diets at daily doses 
of 300-600 mg/kg and 137 o r 275 rag/kg respectively produced similar effects 
to propranolol. Toxicological evaluation of nadolol which included data on 
turaourigenicity revealed that this drug was not tumourigenic in either 
species (Sibley et al, 1978).
Aims of Project
Despite extensive research and safety evaluation carried out on p>-adrenergic 
blocking agents, there are still problems associated with the potential 
toxicity of this class of drugs. Long-term animal carcinogenicity studies 
have led to the identification of tumours in rodents with some of these 
compounds, although some of these findings are equivocal and need further 
examination. There are however, no available data on short-term tests 
of their potential mutagenicity. The FDA has suggested that the whole class 
of drugs might be potential carcinogens possibly because of their expected
action on cellular adenylate cyclase/cyclic AMP and guanylate cyclase/ 
cyclic GMP levels. When the practolol toxicity arose, a new potential 
manifestation of toxicity, possibly involving mucus and glycoprotein 
synthesis became apparent. The aims of the present study were therefore 
four-fold.
a) To investigate the potential carcinogenicity of some beta-adrenergic 
blocking agents using a short-term carcinogenicity test involving the 
measurement of their effects on the activities of biphenyl 2- and 4- 
hydroxylase and ethoxyresorufin O-deethylase, catalysed by cytochrome 
P-448 known to be formed by carcinogens (Bridges et al, 1973? Burke
et^  aj^ , 1977? Atlas and Nebert, 1976? Burke and Mayer, 1975), as well as 
other drug-raetabolizing enzyme parameters.
b) To determine the potential mutagenicity of some of these agents using 
short-term mutagenicity tests such as the Ames’ bacterial (McCann et al,
1975) and mammalian micronucleus (Heddle, 1973? Schmid, 1975) tests.
c) To investigate whether the practolol toxicity is a direct result of 
pharmacological effect of beta-blockade involving synthesis of mucus 
glycoproteins.measured by the effects of some of these agents on the 
rates of incorporation of radiolabelled sugar and amino acid precursors 
into rat gastrointestinal mucus glycoprotein as used by Johnston (1977) 
for the study of the ulcer-healing effect of carbenoxolone.
d) To study their effects on cellular levels of adenylate cyclase/cyclic 
AMP and guanylate cyclase/cyclic GMP to ascertain whether these effects 
can be implicated in glycoprotein synthesis and the incidence of 
malignancy as has-been suggested for some carcinogens and tumour- 
promoting agents (Macdonald et al, 1977? Delaunay and Schapira, 1974; 
Parke, 1977b; Trosko et al, 1975)*
CHAPTER TWO
EFFECT OF SOKE BETA-ADRENERGIC BLOCKING AGENTS ON RAT 
HEPATIC MICROSOMAL MIXED-FUNCTION OXYGENASE SYSTEM
INTRODUCTION
Long-term animal studies are the most widely used and generally accepted 
methods for the screening of chemicals for their carcinogenic potential. 
However, these studies have proved to be very expensive and time consuming 
making it much less practical to screen large numbers of compounds, and 
often results are equivocal due to high incidence of spontaneous tumours 
in control animals and ambiguous distinction of tumours, namely benign and 
malignant tumours, hyperplasia, metaplasia and neoplasia (Fishbein, 1976).
A wide variety of more economical short-term tests of high predictive value 
are currently developed to identify compounds with carcinogenic potentials. 
Many of these tests are designed to detect agents that cause damage to DNA 
(i.e. mutagens) in bacterial, mammalian or human cultured systems, since 
there appears to be a good correlation between mutagenesis and carcinogenesis 
(Miller and Miller, 1975? Ames et al, 1975b; Jenssen and Ramel, 1980). One 
of the most successful of these is undoubtedly the Ames test, which is an 
in vitro test system employing specially constructed strains of Salmonella 
typhimurium as sensitive indicators of DNA damage, and mammalian liver 
extracts fortified with the necessary cofactors for the metabolic activation 
of carcinogens to their mutagenic forms (McCann et al, 1975; McCann and Ames,
1976). An in vivo test system has also been developed for determining the 
DNA damage caused by mutagens and carcinogens known as the micromucleus test 
(Schmid, 1975)* Although this test is less sensitive than the Ames test 
it has an almost parallel specificity and predictive value (Jenssen and Ramel 
1980).
It has been suggested that not all organic carcinogens produce tumours by 
the electrophilic theory of DNA attack (Pitot and Heidelberger, 1963? 
Weisburger, 1973)* A mechanism has-been suggested for such non-mutagenic
carcinogens for the expression of their tumorigenic potential; called 
epigenetic mechanism (Williams, 1977)* Turaorigenic compounds acting via 
this mechanism may act in a manner analogous to differentiation, where cells 
of demonstrably equivalent genetic constitution turn into types that become 
more increasingly diverse. Irreversible changes induced by specific mole­
cular species in the cell such as-a modification of regulator-gene activity 
for a short period of time could give rise to a variety of phenotypes in the 
absence of genetic damage and could result ultimately in the production of 
tumours (Weiss, 1968; Magee, 1977; Pitot and Heidelberger, 1963)* This 
phenomenon may account for the tumours produced by chemicals such as 
Saccharin,, phenobarbitone, chloroform, carbon tetrachloride, dieldrin and 
DDT amongst others. The limited evidence available indicates that most of 
the possible epigenetic carcinogens (carcinogens acting through epigenetic 
mechanisms) are species specific in their effects and produce tumours only 
after prolonged exposure to the chemical at high dose levels. In these 
cases normal dose-response relationships may be inappropriate and the 
definition of a critical toxic effect level, threshold dose, may be 
necessary below which exposure to the chemical would not be hazardous and 
may be much higher than the *safe level* suggested by analogy with mutagenic 
carcinogens operating via a genotypic mechanism (Cornfield, 1977? Graham <rt 
al, 1975).
Carcinogens are known to exert various effects on the endoplasmic reticulum 
and these appear to provide promising alternatives to carcinogen testing.
The microsomal oxygenation of the model substrate biphenyl, leads to the 
production of two major products namely, 2-hydroxybiphenyl and 4—hydroxy— 
biphenyl. Both products are catalysed by cytochrome P-448 whilst cytochrome 
P-450 catalyses only the 4-hydroxylation (Bridges ^ t al^ 1973; Atlas and' 
Nebert, 1976). This specificity of the 2-hydroxylation by cytochrome P—448 
and the known formation of cytochrome P-448 by chemical carcinogens has 
suggested a correlation between the effects of carcinogens on the endoplasmic
reticulum and an increase in enzymic 2-hydroxylation of biphenyl(Creaven and 
Parke, 19665 McPherson et al, 1976). Furthermore, the irreversible 
displacement of ribosomes from the endoplasmic reticulum (degranulation) 
by carcinogens (Williams and Rabin, 1971? Delaunay and Schapira, 1974) 
has suggested a further relationship between the degranulation of the 
endoplasmic reticulum and the enzyme biphenyl 2-hydroxylase (Parke, 1977a). 
Carcinogens have also been shown to produce changes in other drug metabolizing 
enzymes (Feuer and Granda, 1970) as well as ethaxyresorufin O-deethylase 
activity which is known to be catalysed by cytochrome P-448 (Atlas and 
Nebert, 1976; Burke and Mayer, 1975? Burke et al, 1977)•
Significant interaction among cardiovascular drugs occur with induction or 
inhibition of hepatic metabolism of drugs. A number of different drugs 
can affect the hepatic microsomal enzyme system that are responsible for 
metabolism of various drugs (Bums and Conney, 1965? Gelehrter, 1976). 
Chemically important interactions due to induction and inhibition of hepatic 
microsomal enzymes have been observed with some cardiovascular agents.
(Data et al, 1976; Ki$rbre, 1966; Kutt et al, 1968; Garrett son et al, 1969 
Soda and Levy, 1975? Lumholtz et al, 1975)• The induction or inhibition of 
drug-metabolizing enzyme activities by beta-adrenergic blocking agents may 
exert an important influence on their metabolism as well as on chemicals 
such as food additives that are generally present in human diet. This may 
lead to beneficial effects if the foreign compounds are rendered inactive, 
but harmful when toxic metabolites are formed.
Long-term animal carcinogenicity studies with beta-adrenergic blocking agents 
have produced equivocal results (Paget, I963; A1cock and Bond, 1964; Howe, 
1965; FDA report, Drug Bulletin, 197®? Boyd and Martin, 1977; Smith and 
Butler, 1978; Newberne et al, 1977? Wiekel and Kelly, 1979)• However 
short-term studies of their potential carcinogenicity through epigenetic 
mechanisms have not been investigated. It was therefore of great interest
to investigate the effects of pretreatment of rats with beta-adrenergic 
blocking agents on the cytochrome P-450 and P-448 - mediated hepatic 
microsomal mixed-function oxygenase system as well as other drug-metabolizing 
enzyme parameters to ascertain their carcinogenic potential and possible 
implications in drug interactions.
EXPERIMENTAL
Materials
Biphenyl was twice crystallized from $6% ethanol (M*P* 60 - 70°C)
4-hydroxybiphenyl and 2-hydroxybiphenyl were twice recrystallized from 
methanol (M.P* 166 - l67°C) and light petroleum (M.P. 56-57°C) respectively 
(Burke, 1972). Glucose 6-phosphate (monosodium salt), NADP+, glucose
6-phosphate dehydrogenase (type 111) and 3-methylcholanthrene (Sigma 
Chemical Co* London)* 7-Ethoxyresorufin and resorufin standard (Pierce 
Chemical Co. Rockford 11, USA)* Ethylmorphine hydrochloride (May and Baker, 
Dagenham, Essex, U.IC).
The beta-adrenergic blocking agents were obtained from the respective 
drug companies as gifts* Atenolol ”free base” (Tenormin), pronethalol 
hydrochloride, propranolol hydrochloride and practolol (Imperial Chemical 
Industries (ICI) Ltd, Cheshire, U K) Acebutolol hydrochloride (Sectral)
May and Baker* Phenobarbitone sodium ^British Drug Houses (BDH) Ltd,
Poole, U.k3 were used as purchased*
All other chemicals used were either of the analytical or general reagent 
grade.
Animals
Male Wistar albino rats (l50-200g) were kept in litter-mate cage groups 
with a maximum of four animals per group* Water and food (Spratt*s 
laboratory chow) were provided ad libitum* The animals were killed between 
10*00 and 11*00 am*
Treatment of animals
The beta-adrenergic blocking agents were administered daily as single 
oral doses for three consecutive days* They were administered in 
aqueous solution (lml/lOOg wt) at three dose levels; 5* 50, 150 mg/kg*
Controls for atenolol and practolol received equivalent volumes of vehicle 
(0«1M Citric acid/Na^HPO^ buffer, pH6*5) whilst the remaining controls 
received nothing* Phenobarbitone (75«g/kg) in saline 0*9#N*Cl(w/v) and
3-aethylcholanthrene. (25®g/kg) in corn oil were administered intra- 
peri toneally (i.p)[p*2ml/100g wt*3 and control animals received saline 
and com oil respectively*
Preparation of Tissue Homogenate
The animals were killed by cervical dislocation 24 hours after administration 
of last dose* The livers were rapidly removed and placed in l*15$(w/v)KCl, 
brought to pH7*6 by addition of NaHCO^ solution, blotted with filter paper 
weighed and immersed in cold 1.15#(w/v) KC1* The weighed livers were 
homogenized in a Potter-Elvehjem homogenizer (Size C,A^.H*Thomas and Co* 
Philadelphia P*A* USA) by using three strokes (10 seconds each) of the 
pestle, power-driven at about 2,500 rev/min* Homogenates (300mgslml) were 
poured into 50 ml polycarbonate centrifuge tubes and centrifuged at 11,000 rpe 
in an MSE high speed id for 20 minutes at 4°C using the 8 x 50ml rotor*
The resulting supernatant was transferred into 25 ml polycarbonate tubes 
and further centrifuged at 50,000 rpa in a Beckman ultra centrifuge model 
LS-65 for 40 minutes at 4°C using the 8 x 25ml rotor. The supernatant 
(cytosol) was discarded and the microsomal pellet washed with the respective 
buffer for an assay and resuspended in buffer to give: a 30% microsomal 
suspension*
Biphenyl Hydroxylation
The assay for biphenyl hydroxylation was according to the method of Creaven
ert aJ (1965) as modified by McPherson (1975)* The incubation system 
consisted of the following:
Buffer
Na2HP04/KH2P04 buffer (0.3mM> pH7*6
TEST(ml)
1*10
BLANK(ml)
1.10
NADPH regenerating system
Glucose 6-phosphate 50 nmoles
NADP+ 10 nmoles
Glucose 6-phosphate dehydrogenase 4 units
0.20 0.20
MgSO. (3*3®M) 0 .3 0 0.30
Microsomal suspension (30%) 0.20 0.20
Substrate
Biphenyl l4mM in 1.15%(w/v)KCl 
containing !•£>%( w/v) Tween 80
Total incubation volume
* Addition after incubation
0.20
2.00
0.20*
2.00
After an incubation period of 10 minutes at 37 C in a shaking water bath 
(100 cycles/rain), the reaction was terminated by addition of 0«5ml 
n-Haptane containing l»5#(v/v) isoamyl alcohol (7«l) was then added to all 
the tubes, extracted for 15 minutes on a rotary shaker and centrifuged at 
2,000rpm for 10 minutes. Aliquots (2ml) of the organic layer were with- ' 
drawn and added to tubes containing 5« 1 0.1N NaOH. Further extraction was 
carried out for 10 minutes on the rotary shaker after which the tubes were 
centrifuged at 2000rpm for 15 minutes. After phase separation, the organic
layer was aspirated off and aliquots (2ml) of the aqueous layer put 
into fluorimetric cuvettes. 0.5N Succinic acid (0.5«l) was added to 
adjust the pH to 5*5*
The 4-hydroxybiphenyl standard incubation mixture was similar to the 
blank but the volume of buffer was reduced by 0*5^1 and substituted with 
the same volume of O.lmM 4-hydroxybiphenyl in 5% ethanol. • In the case of 
the 2-hydroxybiphenyl standard 0.1ml of buffer was replaced by the same 
volume of O.lmM 2-hydroxybiphenyl in 5% ethanol.
The 2-and 4-hydroxybiphenyls were measured using a Perkin-Elmer MPF 3 
spectrophotofluorimeter at emission wavelengths 4l5na and 33&nm with 
excitation wavelengths 295nm and 275nm respectively.
From the reading at 338nm with A 275nm 4-hydroxybiphenyl can beexc.
calculated since the 2-isomer does not interfere at this wavelength. From
the reading obtained at 4l5nm with X 295n®i 2-hydroxybiphenyl can beexc.
determined after allowing for the contribution of the 4-isoaer at this 
wavelength. This contribution was calculated as follows:-
Reading of 4-hydroxybiphenyl ^ amount of 4-hydroxybiphenyl in unknov
standard at 4l5nm amount of 4-hydroxybiphenyl in standbr
7-Ethoxyresorufin 0-deethylase
Hepatic microsomes catalyse the O-deethylation of ethoxyresorufin to 
resorufin. Both compounds are highly fluorescent, and the reaction can be 
monitored continuously in a fluorimeter.
The method used for this assay is that of Burke and Mayer (1974). The 
reaction mixture comprised 2ml sodium phosphate buffer (0.1M) pH7*8, 20 jul 
microsomal suspension (30%) and 10 Ail ethoxyresofurin (50 uM in methanol).
The reaction rate was measured at 37°C in a Perkin-Elraer MPF-3 
spectrophotofluorimeter at an emission wavelength of 586am and at an 
excitation wavelength of 5i0nm. A baseline was initially drawn before 
addition of 10 ;ul NADPH (50 mM) to initiate the reaction which was 
followed for 2 minutes. A standard reference was prepared in which 
ethoxyresorufin has been replaced by 10 jul resorufin standard (O.lmM) 
and used in calculating the amount of product formed.
Cytochromes and P-450
The method employed is essentially that used by Ullrich (1969). Equal 
volumes of microsomal suspension (2.5<b1 containing approximately 2mg/ml 
protein in 0.3M Na^HPO^/KHgPO^ buffer pH7*6) were added to two matched 
cuvettes. 5 .hi NADH (lOmg/ml buffer)were added to test cuvette, mixed 
and the difference spectrum for cytochrome b recorded between 390nm ***& 
430nm wavelengths in a Pye Uni cam SP1800 dual beam spectrophotometer. Few 
granules of sodium dithionite were added to both cuvettes to reduce 
cytochrome P-450. The test cuvette was gently gassed with carbon monoxide 
for about 30 seconds. The difference spectrum for cytochrome P-450 was 
recorded between wavelengths 430nm and 500nm. The amount of cytochromes 
b and P-450 in samples were calculated using the extinction coefficients, 
of 170 mM“1cm"1 ^ 4 24*®4o9^ and 910M" 1 cm-1 respectively
(Ullrich, 1969).
NADPH Cytochrome c Reductase
The principle of the assay is the measurement of the rate of reduction of 
cytochrome c. The method used in the assay was a modification of that of 
Masters et al (1967) and the incubation mixture is as follows:-
Potassium phosphate buffer (0.05M) 
pH 7*7 containing 10 Si EDTA
TEST(ml)
0.8
BLANK(ml) 
1.0
Microsomal suspension (30$) 0.2 0.2
Cytochrome c (72 nM) 1.0 1.0
0.2*
2.2 2.2
NADPH (10~3M)
Total incubation volume
* Added to initiate reaction
The reaction was followed by recording the difference in absorbance 
between test and blank at 550hm. The concentration of reduced cytochrome 
c was determined using extinction coefficient of 21mM"’*cni~^  (Masters et al, 
1965).
Ethylmorphine N-demethylase
The procedure of Holtzman et al, (1968) was used in which the formaldehyde 
produced was measured by the formation of a yellow complex by method of 
Nash (1953)* The incubation mixture was as follows:-
Buffer
Tris-HC1(0.15M) pH 7.4 
NADPH regenerating system 
NADP+
Glucose 6-phosphate 
MgCl
1.5 nmoles 
30 nmoles 
15 nmoles
Glucose 6—phosphate dehydrogenase 2 units 
Microsomal suspension (30$)
Ethylmorphine hydrochloride (3mM)
Total incubation volume
TEST(ral)
0.9
1.0
0.1
1.0*
BLANK(ml)
1.9
1.0
0.1
3.0 3.0
* Incubation mixture warmed for 5 minutes at 37 0 before its addition.
o
The mixture was incubated at 37 C for 10 minutes in a shaking water 
bath (100 cycles/min). The reaction was terminated with 1ml 5$(w/v) 
ZnSO^. Saturated BaCOH)^ (1.5ml) was added and shaken followed by 
addition of saturated sodium metaborate (0.5ml) with further mixing.
The resulting mixture was centrifuged at 2,C00rpm for 20 minutes in a 
Mistral 6L centrifuge and the formaldehyde formed determined by method 
of Nash (1953)* To the supernatant(3ml) was added an equal volume of 
freshly prepared Nash reagent B (2raM ammonium acetate, 0.05M acetic acid 
and 0.02M acetylacetone). The mixture was shaken and incubated at 37°C 
for 40 minutes in the shaking water bath. The resulting yellow complex 
was measured at 4l2nra in a Cecil 20 spectrophotometer after bringing the 
solution to room temperature. The formaldehyde produced by reactions not 
involving drug substrate was corrected by preparation of tissue blanks in 
which only the substrate has been omitted. The concentration of formal­
dehyde formed was determined by using the extinction coefficient of 8.0mM 
cm*"* (Nash, 1953)*
Protein Determination
The method used was based upon the colourimetric determination of protein 
by Lowry est al, (l95l)«
Samples were diluted with 0.5N NaOH to give an amount of protein of about 
0*5flig/ml. A 1ml aliquot of the diluted sample was then put into a test- 
tube. 5ml of a freshly prepared copper reagent* were added and mixed. 
This was allowed to stand for 10 minutes before adding 0.5ml Folin- 
Ciocalteau phenol reagent (diluted 1 in 3 with distilled water). The 
contents were immediately mixed and the resulting blue colour was read 
after 35 minutes in a Cecil 20 spectrophotometer at 720nm. The tubes
•were run in duplicate. Suitable blank and standards 0-1(mg/ml) bovine 
serum albumin were carried through the same procedure.
* Copper reagent comprised:-
1# CuSO^. 5H20 
2$ Potassium-sodium tartrate
0.5 ml 
0.5 ml
RESULTS
Effect of Phenobarbitone, 3-*a©thylcholanthrene and some Beta-adrenergic 
Blocking Agents on sotae Hepatic Drug-metabolizing Parameters in the Rat
It appears from the study that none of the beta-adrenergic blocking agents
significantly affected the liver wt/body wt*, microsomal protein, cytochromes
bg. and P-450 contents at any of the dose levels. In addition atenolol and
practolol did not significantly affect the hepatic microsomal mixed-function
did
oxygenases activities. However, propranolol, pronethalol and acebutolol£at 
the highest dose level of 150mg/kg. Thev stimulatory effect on ethoxyresorufin 
O-deethylase by propranolol and pronethalol appear to be dose-dependent. 
Propranolol also significantly enhanced both biphenyl 2-and 4-hydroxylase 
activities whilst pronethalol only enhanced the biphenyl 4-hydroxylase 
activity at the highest dose level of 150mg/kg. None of the beta-adrenergic 
blocking agents at any dose level significantly changed the activities of 
ethylmorphine N-demethylase and NADPH^ cytochrome c reductase (Tables 2.1 - 
2.10).
Fhenobarbitone (75as/^g) and 3-raethylcholanthrene (25»g/kg) non-carcinogen 
and carcinogen controls respectively, significantly increased liver wt/ 
body wt. without any changes in microsomal protein. However, 3-CH®thycholan- 
threne induced both cytochromes b^ and P-450 whilst phenobarbitone induced 
only cytochrome P-450. The activity of ethoxyresorufin O-deethylase activity 
was enhanced significantly (90-fold) and that of ethylmorphine N-demethylase 
inhibited by 3-°©thylchoianthrene. Phenobarbitone on the otherhand 
significantly enhanced ethylmorphine N-demethylase activity without markedly 
affecting ethoxyresorufin O-deethylase activity. 3-»©thylcholanthrene 
stimulated both biphenyl 2-hydroxylase (7 -fold) and biphenyl 4-hydroxylase 
(2-fold) whereas phenobarbitone enhanced biphenyl 4-hydroxylase (2 -fold) 
without significant stimulation of biphenyl 2-hydroxylase (Table 2.11)
Effect of Combined Administration of Propranolol and
3-methylcholanthrene on Rat Hepatic Drug-metabolizing Parameters
Administration of two different dose levels of propranolol (50,lOOmg/kg) 
together with 3-methylcfaolanthrene (20mg/kg) significantly increased liver
wt/body wt. and cytochromes b and P-450 contents in the rat. It appears
5
that these changes decreased with increasing propranolol concentration as 
compared to 3-methylcholanthrene control* The enhancement of biphenyl' 
2-hydroxylase and ethoxyresorufin O-deethylase activities by ^ -s^thylcholanthrene 
were ftirther augmented by combined administration with propranolol and these 
changes appear to increase with increasing propranolol concentration (i.e* 
combined effect appear to be additive). However the reverse is true for 
biphenyl 4-hydroxylase, ethylmorphine N-demethylase and NADPH cytochrome c
a
reductase activities; the enhancements shown by 3**®ethyl cholanthrene for 
biphenyl 4-hydroxylase is slightly inhibited whilst the inhibition of 
ethylmorphine N-demethylase and NADPH cytochrome c reductase is slightly 
counteracted by combined administration with propranolol (Tables 2*12, 2*13)*
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DISCUSSION
Long-term animal carcinogenicity studies with beta-adrenergic blocking 
agents such as pronethalol, propranolol, alprenolol, practolol, pamatolol 
and talomolol, have demonstrated their potential as tumour promoters 
although most results have been equivocal necessitating repeat studies*
(Paget, 1963; Alcock and Bond, 1964; Howe, 1965; Smith and Butler, 1978;
Boyd and Martin, 1977; FDA report, Drug Bulletin, 1978; Newbeme et al,
1977)* It has been suggested that this whole class of drugs may be potential— 
tumour promoters because of their probable effects on cellular adenylate 
and guanylate cyclase and cyclic nucleotide levels.
Short-term studies of the effects of some beta-adrenergic blocking agents 
namely; acebutolol, atenolol, practolol, pronethalol and propranolol, on 
rat hepatic endoplasmic reticulum as potential epigenetic carcinogens have 
been investigated as measured by their effects in vivo on the in vitro rat 
hepatic microsomal mixed-function oxygenase system and other drug-metabolizing 
parameters.
The absence of any significant changes in liver wt./body wt., microsomal 
protein, cytochromes b and P-450 contents, NADPH cytochrome c reductase 
and ethylmorphine N-demethylase enzyme activities by any of the beta- 
adrenergic blocking agents studied, suggests that none of these agents is . 
a potent inducer of rat cytochrome P-450-mediated microsomal raixed-function 
oxygenase system.
It appears that atenolol, practolol and acebutolol by their non-stimulatory 
effect on biphenyl 2-hydroxylase at any dose level studied behaved,at very 
high dosage,in a manner characteristic of phenobarbitone which does not 
significantly induce the formation of cytochrome P-448 known to catalyse both
the 2-and%4-hydroxylation of biphenyl (Bridges eit al, 1973; Atlas and 
Nftbert, 1976). However, the enhancement of biphenyl 2- and 4-hydroxylase 
activities by propranolol and to some extent pronethalol,at the highest 
dose level of 150mg/kg, suggest their induction of cytochrome P-448 
formation.-This is further supported by the apparent dose-dependent 
stimulation of the enzyme ethoxyresorufin O-deethylase by propranolol and 
pronethalol which is also catalysed by cytochrome P-448 (Burke et al, 1977; 
Burke and Mayer, 1975)* However, the stimulation of this enzyme by acebutolol 
at the highest dose level of 150 mg/kg suggests the probable formation of 
cytochrome P-448 although this did not significantly affect the stimulation • 
of biphenyl 2-hydroxylase. These findings suggest that propranolol and 
pronethalol are inducers of the rat hepatic cytochrome P-448-mediated 
microsomal mixed-function oxygenase system. At the normal human dosage 
(^ rag/kg) however, none of the beta-adrenergic blocking agents significantly 
enhanced the hepatic microsomal mixed-function oxygenases activities, although 
it should be borne in mind that rates of oxidative metabolism of drugs and 
other xenobiotics in animals are many times higher.than in man (Parke and 
Ioannides, 1980).
The observation that atenolol and practolol and to some extent acebutolol 
did not significantly affect both cytochrome P-450 and P-448-raediated hepatic 
microsomal mixed-function oxygenases activity suggests that their metabolic 
effects may not significantly affect their own rates of metabolism or of 
other chemicals such as food additives generally present in human diets.
Hence they may not be involved in drug-interactions as inducers or inhibitors 
of the microsomal mixed-function oxygenase system as has been suggested for 
some cardiovascular agents (Data et al, 1976; Kiorbe 1966; Kutt et al, 1968; 
Garrettson et al, 1969; Soda and Levy, 1975; Lumholtz et al, 1975).
However, pronethalol and propranolol by their induction of hepatic microsomal 
cytochrome P-448-mediated mixed-function oxygenase system may affect their
own rates and modes of metabolism as well as other chemicals leading to 
possible drug interactions and the formation of products with probable 
tumourigenic potentials.
The effects of beta-adrenergic blocking agents on ethoxyresorufin 0- 
deethylase, biphenyl 2- and 4-hydroxylase activities appear to relate 
to their rates of gastrointestinal absorption, modes of metabolism and 
clearance which are a reflection of their polarities and hence lipid- 
solubilities. The more lipid-soluble beta-adrenergic blocking agents; 
pronethalol, propranolol and to some extent acebutolol, are mainly 
metabolized and eliminated by hepatic mechanisms (Bond and Howe, 19^7? 
Kiechel and Meier, 1978) and enhance significantly these enzyme activities, 
whereas the less lipid-soluble ones; practolol and.atenolol which are 
only slightly metabolized by the liver and eliminated by renal mechanisms 
(Kiechel and Meier, 1978) do not significantly affect these enzyme 
activities. These degrees of enhancements caused by the beta-adrenergic 
blocking agnets are in the order, propranolol>pronethalol>acebutolol> 
atenolol and practolol (no induction) and are a direct reflection of their 
degrees of hepatic metabolism. The marked enhancement of biphenyl 2- 
and 4-hydroxylase activities by propranolol as.opposed to pronethalol at 
the highest dose level of 150rag/kg may probably be explained by its 
extensive hepatic ’first-pass” effect (Howe, 19&5; B°nd and Howe, 1967; 
Kiechel and Meier, 1978)•
The action of pronethalol and propranolol on cytochrome P-448 mediated 
biphenyl 2- and 4-hydroxylase as well as ethoxyresorufin 0-deethylase 
activities show similar characteristics as suggested for epigenetic 
carcinogens such as saccharin and DDT, amongst others, which stimulate 
these enzymes to about the same extents [Tong, 1979; Tong, 1979
(unpublished The mutagenic carcinogen, 3=!,mehylcholanthrene,
by its enhancement of these enzymic activities many orders of 
magnitude higher than those shown by propranolol and pronethalol suggest 
that it may be acting through a mechanism different from these beta- 
adrenergic blocking agents at the cellular level as at the genetic level 
This is reflected in the augmentation of the activities of some hepatic 
microsomal mixed-function oxygenases on combined administration of 
propranolol and 3-raethylcholanthrene over those caused by 3~me^yi*" 
cholanthrene alone as well as differences in their individual effects*
It may be inferred from these findings that propranolol and pronethalol, 
if administered at prolonged high dosage, may act as potential tumour 
promoters as has been observed in long-term animal studies with prone— 
thalol (Paget, 1963; Alcock and Bond, 1964; Howe, 1965) and propranolol 
(Smith and Butler, 1978; Boyd and Martin, 1977)» and may be involved in 
drug interactions by their induction of cytochrome P-448 which may lead 
to adverse drug reactions including tumour formation*
CHAPTER THREE
THE MUTAGENECITY TESTING OF SOME 
BETA-ADRENERGIC BLOCKING AGENTS
INTRODUCTION
A close correlation has been found between chemicals with a mutagenic 
activity and those that cause malignant tumours in experimental animals 
(McCann et al, 1975; Purchase eit al, 1978), suggesting a common molecular 
mechanism for these two processes as proposed by Brusick (1977) and shown 
below. For that reason, short-term tests for mutagenicity can also be 
applied for the prediction of carcinogenic activity.
Since the number of chemicals identified or suspected as being human 
carcinogens is relatively small (Tomatis et al, 1979), most studies on 
the validation of short-term tests for the predictive value of carcinogenic 
effect have involved chemicals for which the presence (or absence) of a 
carcinogenic effect has been proved in laboratory animals (McCann et aul, 1975; 
Purchase et. al, 1978; Rosenkranz and Poirier, 1979; Simmon, 1979; Sugiraura 
et al, 1976).
As increasing numbers of short-term assays are now available (Hollstein
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et al, 1979), it seems important to define their reliability, and hence 
their sensitivity (the capacity to identify carcinogens), specificity 
(the power to discriminate between carcinogens and non-carcinogens) and 
predictive value have been proposed (Cooper et al, 1979; Malaveille, 1977; 
Purchase et aJ, 1978)*
In validity evaluation reported by Bartsch et ad (I98O), it was shown that 
the Ames test has a predictive value of 92% which confirmed an earlier 
finding by McCann et aJ^  (1975)• However, this value was strongly influenced 
by the way in which the chemicals were selected and by the proportion of 
carcinogens in the series of chemicals tested. Another limitation in the 
use of the Ames test is that it only reflects point mutations and therefore 
its combination with other tests that respond to other types of genetic 
damage is of great importance.
Recent publications (Friedman, 1977; Wild, 1980) have called attention to 
the value of the micronucleus test as a fast and cheap screening system for 
genetic hazards of environmental agents. This assay responds both to 
chromosome-breaking agents and to agents causing non-disjunction of 
chromosomes (Jenssen and Rarael, I98O; Maier and Schmid, 1975; Seiler, 1976)., 
Furthermore it reflects the situation in vivo in mammals and can also be 
applied for investigations in man (Goetz et al, 1975, 1976; Jenssen and 
Huttel, 1976; Krough-Jensen, 1977)*
The correlation between the micronucleus test and corresponding cancer data 
have been analysed to evaluate its usefulness as an economical short-term 
assay for the detection of carcinogens (Jenssen and Ramel, 1980).
A comparison of the micronucleus and Ames tests shows that they have an 
average specificity of about 80% and predictive value of about 90% there
was significant difference in sensitivity in favour of Ames test* This 
is reflected in the data on evaluation of the Ames'and micronucleus 
mutagenicity tests in the prediction of chemical carcinogens shown below*
Characterization Definition Ames test Micronucleus 
test
Ames and 
micronucleus
tests combined
(%) (%) (%)
Sensitivity C+M+/C+M++C+M~ 60 58 86
Specificity c “m ~/c ~m ++c “m ~ 82 82 73
Predicitve value c Y / c ¥ +c V 92 89 90
Proportion . of 
carcinogens C+M++C+M**/Total 71 73 72
C M  - Nos* of mutagenic carcinogens C M  - Nos. of non-mutagenic non-
C M  - Nos* of non-mutagenic carcinogens carcinogens
C M  - Nos. of mutagenic con- 
carcinogens
After Jenssen and Ramel (1980)
The metabolizing system (Srf9raix) used in the Ames test is an artificial 
system as compared with the situation in vivo for the micronucleus test 
(Greim, I98O)• Since the co-factors for the deactivating enzymes tend not 
to be present in the S-9 fraction, mainly the activation part of the 
metabolism takes place in vitro, which might lead to an overestimation or 
false positive results in the Ames test* Besides the mutagenicity potency 
of a chemical in the Ames test may be influenced by at least fourteen major 
factors; from choice of bacterial strain to definition of counting colonies 
(Ashby and Styles, 1978)*
However, of the compounds which give positive results in the Ames test,
5256 of those requiring metabolic activation (S-9 activation) were positive
■micronucleus te s t
in the/ and those that were directly mutagenic (not requiring metabolic 
activation) in the salmonella test, 63# were positive in the micronucleus 
test* The disparity (11%) may be explained by differences in metabolic
capacities of the two test systems.
The sensitivity in the micronucleus test depends on the number of poly­
chromatic cells counted as well as the criterion for a positive effect.
In a study by Heddle and Bruce (1977) only a thousand cells/mouse were 
counted in three mice. Furthermore their criterion for a positive effect 
usually meant a 4—5 fold increase of the spontaneous level of micronuclei 
as compared to 2-3 fold increase in the Ames test. A count of four thousand 
cells per mouse led to a doubling effect which can be verified statistically.
Although long-term animal carcinogenicity studies have been reported for 
most beta-adrenergic blocking agents (Paget, 1963; Alcock and Bond, 1964; 
Howe, 1965; Smith and Butler, 1978; Boyd'and Martin; 1977; Newbeme et al, 
1977; Wiekel and Kelly, 1979; Sibley, 1978; FDfl report, Drug Bulletin,
1978), there are no available data on their short-term mutagenicity studies. 
It was therefore of great interest to employ the Ames and micronucleus tests 
to screen a number of this class of drugs for their mutagenicity potentials.
EXPERIMENTAL
AMES TEST
Growing and Storage of Bacterial Test Strains
The bacterial strains were kept in frozen nutrient broth cultures in 
aliquots of 2ml at -70°C with 8.0% dimethylsulphoxide (DMSO) in 10ml 
sterile glass screw-capped vials with rubber-lined screw caps. Duplicate 
frozen cultures of each tester strain was prepared. One was stored as a 
master copy and was only used when there was need to regenerate frozen 
stocks. The other was used routinely to obtain fresh cultures from 
mutagenesis testing by scraping a sterile hypodermic needle over the surface 
of the frozen culture and inoculating 5®1 of nutrient broth. This was 
incubated overnight for a maximum of 16 hours in a shaking water incubator 
at 37°C.
Checking out Tester Strains
All strains were tested for the presence of their mutations prior to their 
use in mutagenesis test:
a) The mutation in the histidine operon, basic ^ to the test system was
tested by checking for growth in the presence and absence of histidine
on a minimal medium-agar base. Bacteria of the nutrient broth culture .
were streaked on the agar plate with/without supplementation with 0.1ml
of a solution containing L-histidine and biotin in a final concentration
of 0.1M and 0.5M respectively, as a growth requirement. The plates 
. owere incubated at 37 C overnight. Growth of all strains, was seen only 
where histidine and biotin were present.
b) Sensitivity to crystal violet is a check for the presence of the deep 
rough (rfa) mutation, the loss of the lipopolysaccharide coat on the
bacterial surface, which permits large molecules such as polycyclic 
hydrocarbons to enter. A sterile filter paper disc containing crystal 
violet (lOul of lmg/ml) is placed on a nutrient agar petri dish containing 
0.1ml of the nutrient broth culture to be tested, in a thin overlay of 
agar (Snl) on the bottom minimal-agar. After 24 hours incubation at 
37°C a clear zone of inhibition around the disc indicates the presence 
of the (rfa) mutation which permits large molecules such as crystal 
violet to enter the bacteria and inhibit growth.
c) Two of the tested strains (TA98 and TAIOO) contain a plasiaid expressing 
resistance to ampicillin called R-factor. The R factors are somewhat 
unstable and can be lost from the bacteria. These factors make these 
strains more sensitive for detection of carcinogens not detected by 
TA1535 &*ici TAI537. To check for the presence of R factor IQul of 8mg/ml 
in 0.02 N NaOH of an ampicillin solution was streaked across the surface 
of a nutrient agar plate covered with a top agar layer,(2al). After the 
streak is dry, cultures to be checked are cross-streaked against the 
ampicillin, and after incubation for 12-24 hours at 37°C, strains which 
do not contain the R factor (TA1535 and TA1537) will show a zone of 
growth inhibition around the ampicillin streak, whereas R factor 
containing strains (TA98 and TA100) will not.
Checking Bacterial Growth in Broth Culture
The number of bacteria in the overnight broth culture was determined by
the serial dilution technique (1:10^). An aliquot (O.ltnl) of the contents
of the last dilution was added to a tube containing 2ml top agar, vortex-
mixed and poured onto the bottom agar. This was incubated for 24 hours at
37°C after solidification. The presence of colonies of growth indicated
8
that there were at least 10 bacteria-/0.lml of broth culture.
Induction of Rat Liver Enzymes
The induction procedure was similar to that used by Araes et £l (1975^).
Adult male Wistar albino rats weighing approximately 200g were each given 
an i.p. injection of a mixture of polychlorinated biphenyls, Aroclor 1254, 
in c o m  oil (200 mg/ml) at a dose of 500 rag/kg;. Five days after the 
injection, the rats were killed by cervical dislocation and the liver 
homogenate (S-9 fraction) prepared as described below.
Preparation of Liver Homogenates Fraction (t!S-9M fraction)
Basically, the procedure of Gamer et al (1972) was used. All steps were 
at 0-4°C using cold, sterile solutions and glassware. The liver lobes not 
in contact with the gastrointestinal tract (GIT), to prevent liver contamina­
tion by bacteria of GIT,were placed in pre-weighed beakers containing 1.15% 
KOI (w/v)[approx. lml/g wet liver}. After weighing, the livers were 
transferred to a beaker containing 3 vol. of 1.15$KC1 (w/v) [3ml/g wet^ j 
liver, minced with sterile scissors and homogenized in Potter-Ehlvehjem 
apparatus with a teflon pestle. The homogenate was centrifuged at 9j000g 
for 10 minutes in 8 x 25®1 rotor of MSE high speed 18 centrifuge, and the 
supernatant (S-9 fraction) was decanted and saved. The protein concentra­
tion as determined by method of Lotfry ejb aT (1951) was found to average 40 
mg/ral. The fresh S-9 fractions were distributed in 3®1 portions into small 
plastic tube (5®1 liquid notrogen storage tubes/4-Shore U.S.A., La Jolla, 
California) and stored at -20°C. As required, sufficient S-9 fraction was 
thawed at room temperature and kept on ice; the unused portion was discarded 
at the end of the day.
Materials
Vogel-Bonner E minimal agar plates were obtained from Gibco Biocult,
Paisley, Scotland. Oxoid nutrient broth and Difco-Bacto agar were obtained
from Oxoid Ltd, Hants, England and Difco Lab., Detroit, USA respectively. 
DMSO was spectrophotometric grade from British Drug Houses (BDH) Ltd., Poole, 
England.
NADP, glucose 6-phosphate and the carcinogens MNNG, 9-&®inoacridine, 
2-aminoanthracene and 2-nitrosofluorene were obtained from Sigma Chemical 
Co. Ltd., England. The beta-adrenergic blocking agents pindolol and 
sotalol hydrochloride were gifts from Sandoz Ltd., Leeds, England and 
Bristol Lab. Slough, England respectively. Oxprenolol hydrochloride and 
Metoprolol tartrate were obtained from CIBA-Geigy Labs., V. Essex, England. 
All other chemicals were obtained in the purest form available.
Preparation of Materials 
Bottom agar
This was already prepared minimal-glucose agar medium called Vogel-Bonner
*E* medium and contains 2% glucose and 1.5% Difco-Bacto agar.
Top agar (nordinaryw)
This was a 0.6% Difco-Bacto agar contained in 0*5% NaCl solution. The 
solution was autoclaved at 151b/sq.in. pressure for 15 minutes (conditions 
for sterilization) in a glass dispenser. 10ml sterile 0.5®M L-histidine- 
0*5mM biotin were added per 250ml agar. 2ral of the resulting solution 
were dispensed into sterile capped plastic tubes and allowed to equilibrate 
at 45°C.
Top agar (nviability test”)
This was 0.6% Difco-Bacto agar, contained in 0.5% NaCl solution used for 
dilution, ampicillin and crystal violet tests. 5®1 sterile 0.1M L-histidine
-0.5M biotin were added per 100ml agar.
Nutrient broth
A preparation of a 2.5% (w/v) solution of nutrient broth in distilled 
water was used.
Test compands
The compounds to be tested were prepared fresh daily in sterile DMSO or 
buffer. The appropriate dilutions were made from a stock of lOmg/ml so 
that not more than 100ul of each dilution was used to achieve a particular 
concentration. (A maximum of lOQul DMSO is known to have no significant 
effect on growth of revertant colonies). The concentrations of tests used 
were 1, 10, 100 and 1,000 jig/plate.
Positive controls
Stock solutions of positive carcinogen controls for the various bacterial 
strains were prepared in sterile universal glass tubes with sterile DMSO 
and a maximum volume of 100U1 used to give con centra tions/tube shown below 
in parenthesis.
Bacterial strain Concentration G-ig/tube)
Without S-9 mix With S-9 mix
TA 98 2-nitroso.fluorene (5*0) 2-anthramine (25)
TA 100 MNNG (2.0) 2-anthramine (25)
TA 1535 MNNG (2.0) 2-anthramine (25)
TA 1537 9-aminoacridine (40) 2-anthramine (25)
MNNG N-methyl-N*-nitro-N-nitrosoguanidine 
*S-9W mixture
This was prepared fresh daily from sterile stocks of the following solutions
so that 0 .5ml contained the respective substances in the concentrations 
shown in the third column below*
Stock solution Volume (ml) Concentration/0.5«l S-9®ix
(jjmoles)
MgC12 (80mM) 0.05 4.0
KOI (0*33M) 0.05 16.5
Glucose 6-phosphate (50mM) 0.05 2.5
NADP (40mM) 0.05 2 .0
Sodium phosphate buffer pH 
7.4 (0.2M) , 0.25 5 0 .0
"S-9" fraction 0.05
Total volume 0.50
Assay System
The assay system consisted of the following additions per tube in the
order shown below.
Stock solution
Activation system 
W4J3..9W mix
Non-activation system 
"-S-9" mix
Volume (ml)/tube
Top agar at 45°C 2 .0 2 .0
Solution of test compound/ 
vehicle/positive controls 0 .1 0 .1
Bacterial suspensions 0 .1 0 .1
mix 0.5 -
Buffer - 0.5
Total volume 2.7 2.7
Hie tubes were first mixed briefly, after addition of test compound/ 
vehicle/positive control and then after addition of "S-9" mix/buffer
using a vortex mixer, and poured onto the minimaJL-mediura agar base. The 
plates were incubated at 37°C for 48 hours, after solidification of top 
agar, in an Astell Hearson solid state constant temperature control oven.
The colonies, the revertants of the wild type were counted manually using 
a Fisher colony counter. Each strain had a characteristic spontaneous rate.
MICRONUCLEUS TEST (M.T.)
Materials
Foetal calf serum was obtained from Gibco Biocult, Paisley, Scotland.
Geimsa stain was from Fisons Ltd, Loughborough, England andGeirasa stain 
concentrated buffer pH6.8 was obtained from British Drug Houses (BDH) Ltd., 
Poole, England. Mitomycin c was obtained from Sigma Chemical Co., England.
Animals and Treatment
Adult male CFI outbred mice (6-8 weeks old) were kept in groups of four 
and fed ad libitum on Spratt’s laboratory chow and water. They were given 
two i.p. injections (lml/100g wt.) at three dose levels of test compound and 
an effective dose of positive control (Mitomycin c), at 24 hour interval. 
Control animals received equivalent amount of vehicle in which test compounds 
were dissolved; 0.1M citric acid/K^HPO^ buffer pH6.5 for atenolol, practolol 
and pindolol, and 0.9% NaCl (w/v) for all other compounds. The animals were . 
killed by cervical dislocation 6 hours after administration of second dose.
Preparation of Smears
Essentially, the method of Heddle (1972) as modified by Schmid (1976) was 
used. The femur of the animals was removed Jo toto by cutting through the 
pelvic bones and below the knee. The bone was freed of flesh by means of
scissors and tissue paper. The knee-cap was peeled off to expose 
the proximal end of the femur. The proximal end was then squeezed with 
twizzers and rapidly touched many times in rows across a prewashed micro­
scope slide (washed overnight in absolute methanol and air-dried) that has 
been wetted with a drop of feotal calf serum, at one end, to prevent too 
many cells from sticking. The smear was produced by holding another slide 
60° to the horizontal slide and moving it slightly backwards followed by 
a forward movement to the other end of the slide. The smear was air-dried 
and left overnight in absolute methanol to fix.
Staining and Mounting of Slides
The slides were treated as follows after removal from methanol:
Air dried
i
Washed in buffered distilled water pH6.8 
for 10 minutes
1
Stained for 15 minutes m  Geimsa stain 
(1:10 of buffered distilled water)
l
Excess stain removed by washing slides in 
buffered distilled water
I
Air-dried and underpart of slides cleaned 
with methanol
Cover-slips mounted with DPX
Scoring of Slides
The slides were first screened at 10QX magnification for regions of 
suitable technical quality. In such regions the cells are well spread 
and well stained; vigorous red in mature erythrocytes and strong bluish
tint in polychromatic erythrocytes.
At higher magnification, 1000X, a thousand polychromatic erythrocytes 
were screened for the presence of micronuclei and the number of micro- 
nucleated polychromatic erythrocytes and not the number of micronuclei 
scored. As a safeguard against artifacts the number of micronucleated 
normocytes in the fields containing the thousand polychromatic erythrocytes 
was registered.
RESULTS
Ames Test for Beta-adrenergic Blocking Agents
None of the beta-adrenergic blocking agents at any concentration studied 
showed any marked increases in the number of His+ revertant colonies/plate 
over and above the spontaneous reversion level in the presence or absence 
of an activation system (S-9 mix). However, oxprenolol and propranolol
e
at the highest concentration of 1,000jug/plate showed marked bacteriocidal 
effects on the strains TA9 8, TA100, TA1537 and TA100, TA1537 respectively 
in the ■; absence than presence of an activation system. Positive controls 
however showed marked increases in the number of His+ revertant colonies/ 
plate with all four strains used (Tables 3*1 - 3«9).
Micronucleus Test for Beta-adrenergic Blocking Agents
In the micronucleus test, results show that none of the beta-adrenergic 
blocking agents with the exception of oxprenolol and propranolol, at any 
dose level studied,gave rise to marked increases in the number of micro— 
nuclei/1000 polychromatic erythrocytes over and above the spontaneous 
control levels. Oxprenolol appeared to show a dose-dependent increase in 
the number of micronuclei with a 3-fold increase at the highest dose level 
of 100 rag/kg. Propranolol on the otherhand did not show any dose-dependent 
increase in the number of micronuclei, but at the highest dose level of 60 
mg/kg gave rise to a 2-fold increase. The positive control compound, mito­
mycin c, gave rise to a 5-7 fold increase in the number of raicronuclei at 
the dose level of 3*5 mg/kg (Tables 3•10a-3«10c)•
Table 3.1 Ames1 Mutagenicity Test for Acebutolol
Agent Concentration
(ufl/Plate)
S-9
His+ Revertant Colonies/plate
Strain TA98 TA100 TA1535 TAI537
Spontaneous 0 + . 4l 196 31 19
reversion (Buffer) - 26 216 43 17
Acebutolol 1 + 42 196 20 17
hydrochloride - 25 198 47 14
10 + 34 171 22 15
- 24 187 30 15
100 + 46 190 29 16
- 24 188 43 14
1000 + 40 153 18 17
- 25 144 47 12
Positive control + 888 2217 1417 2003
— 1553 3144 1868 1188
Results are Meansof triplicate determinations
Table 3*2 Ames* Mutagenicity Test for Atenolol
Agent
Concentration
His+ Revertant Colonies/plate
(h9/plate) S-9 Strain TA98 TA100 TA1535 TA1537
Spontaneous 0 + 41 159 32 . 15
reversion (DMSO) - 26 208 35 16
Atenolol 1 + 41 168 34 15
(Tenormin 
"free base") - 31 203 34
10 + 51 187 18 17
- 22 157 43 13
100 + 42 191 16 17
- 22 179 27 16
1000 + 40 195 24 19
- 23 214 34 20
Positive control + 888 1866 2319 1794
• 1553 2745 1945 2298
Results are Means of triplicate determinations
Table 3»3 Ames* Mutagenicity Test for Practolol
Agent
Concentration
(ng/plate) S-9
His+ Revertant Colonies/Plate
Strain TA98 TA100 TA1535 TA1537
Spontaneous 0 + ■ 40 186 29 11
reversion (DMSO) - 24 177 27 6
Practolol 1 49 185 30 14
- 17 196 52 8
10 + 45 177 26 13
- 17 225 46 4
100 + 43 188 27 13
- 21 200 37 4
1000 + 47 161 30 13
- 27 181 34 5
Positive control 888 2721 897 841
....................... -
- 1553 2113 624 752
Results are Means of triplicate determinations
Table 3»4 Ames* Mutagenicity Teat for Pindolol
Agent Concentration (jag/plate) S-9
His* Revertant Colonies/Plate
Strain TA98 TA100 TA1535 1A1537
Spontaneous 
reversion (DMSO)
Pindolol 
("free base")
Positive control
10
100
1000
61 195 43 16
30 159 62 14
65 180 49 15
31 190 52 11
59 180 42 13
37 245 55 13
48 170 46 11
35 254 45 9
62 219 64 12
33 256 77 13
4155 2683 480 365
1377 2051 1807 1690
Results are Means of triplicate determinations
Table 3»5 Ames* Mutagenicity Test for Metoprolol
Agent Concentration(ng/plate) S-9
His+ Revertant Colonies/Plate
Strain TA$8 TA100 TA1535 TA1537
Spontaneous 0 + 21 *234 27 8
reversion (Buffer) - 24 *265 42 9
Metoprolol tartrate 1 + 44 175 46 9
- 24 274 33 14
10 + 31 184 37 7
- 22 257 42 10
100 + 38 200 39 7
- 30 220 38 7
1000 + 28 180 41 6
- 20 277 52 7
Positive control + 1503 2789 524 424
- 1007 1705 1046 897
Results are Means of triplicate determinations
* Unusually high spontaneous reversion value coincided with 
the shaving of mice treated with benzo(a) pyrene on the skin.
Table 3*6 Ames1 Mutagenicity Test for Oxprenolol
Agent
Concentration
(ng/plate) S-9
His* Revertant Colonies/Plate
Strain TA98 TA100 TA1535 TA1537
Spontaneous 0 + *200 *388 41 13
reversion (Buffer) - *145 *332 55 12
Oxprenolol 1 + 188 436 44 10
hydrochloride - 116 301 45 8
10 + 192 429 31 11
- 135 292 51 7
100 + 175 348 44 10
- 86 294 57 7
1000 + 120 192 44 10
- 69 175 44 4
Positive control + 1967 2065 769 142
m 1737 3629 975 409
Resalts are Means of triplicate determinations
* Unusually high spontaneous reversion values coincided with 
the shaving of mice treated with benzo(a) pyrene on the skin
Table 3>7 Ames* Mutagenicity Test for Sotalol
Agent
Concentration 
(u g/plate) S-9
His* Revertant Colonies/Plate
Strain TA98 TA100 TA1535 TA1537
Spontaneous 0 + *142 66 36 9
reversion (Buffer) - 24 62 47 8
Sotalol 1 + 163 75 36 9
hydrochloride - 29 97 46 11
10 + 171 48 31 8
- 28 74 41 14
100 + 202 51 32 8
- 26 70 48 14
1000 + 196 54 52 15
21 68 40 12
Positive control + 1944 845 715 150
■ - 1103 2209 1115 1163
Results are Means of triplicate determinations
* Unusually high spontaneous reversion value coincided with the 
shaving of mice treated with benzo(a) pyrene on the skin.
Table 3.8 Ames* Mutagenicity Test for Pronethalol
Agent Concentration 
(u g/plate)
S-9
His* Revertant Colonies/Plate
Strain TA98 TA100 TA1535 TA1537
Spontaneous 0 + 60 182 42 4
reversion (Buffer) - 72 242 36 6
Pronethalol 1 + 49 160 28 5
hydrochloride - 56 239 33 7
10 + 55 161 25 5
- 59 168 28 9
100 + 57 156 32 8
- 53 251 36 8
1000 + 45 132 50 8
- 50 170 38 9
Positive control + 2427 2715 737 245
2152 2608 3448 1267
Results are Means of triplicate determinations
Table 3.9 Ames1 Mutagenicity Test for Propranolol
Agent Concentration(pg/plate) S-9
His+ Revertant Colonies/Plate
Strain TA98 TA100 TA1535 TA1537
Spontaneous 0 + 43 192 33 10
reversion (Buffer) - 26 224 61 9
Propranolol 1 + 43 205 42 8
hydrochloride - 27 211 40 16
10 + 48 211 40 18
- 31 165 34 8
100 + 45 195 24 16
- 27 174 45 8
1000 + 35 123 17 8
- 22 65 48 3
Positive control + 888 : 2715 681 180
- 1553 2519 2241 449
Results are Means of triplicate determinations
Table 3«10a Micronucleus Test for some Beta-adrenergic Blocking Agents
Treatment Dose(mg/kg)
----- - , .. —  ....... . .- l.a
Nos, of micronucleated 
polychromatic erythrocytes/ 
1000 polychromatic 
erythrocytes counted
Nos. of micronucleated 
normocytes/1000 polychromatic 
erythrocytes counted in the 
same field
Control 0 6 None
Acebutolol 30 9 f!
100 9 n
150 10 »
Oxprenolol 25 7 ti
50 14 w
100 23 M
Positive
control 3.5 33 1
Control 0 4 None
Sotalol 50 6 1
100 7 it
150 7 it
Metoprolol 50 7 it
100 9 it
150 9 it
Positive
control 3-5 26
it
Results are Means for four animals
Table 3.10b Micronucleus Test for some Beta-adrenergic Blocking Agents
•Treatment Dose(rng/kg)
Nos of znicronucleated > 
polychromatic erythrocytes/ 
1000 polychromatic 
erythrocytes counted
Nos. of mieronucleated 
normocytes/1000 polychromati 
erythrocytes counted in the 
same field
Control 0 3 None
Atenolol 50 4 it
100 4 n
150 4 n
Practolol 50 3 tt
100 5 tt
150 5 tt
Positive
control 3-5 25
it
Control 0 5 None
Propranolol 20 8 i i
40 13 n
60 14 it
Pronethalol 20 6 tt
40 5 it
6o 9 tt
Positive
control 3*5 36
1
Results are Means for four animals
Table 3»10c Micronucleus Test for some Beta-adrenergic Blocking Agents
Treatment
Dose
(mg/kg)
Nos of micronucleated 
polychromatic erythrocytes/ 
1000 polychromatic 
erythrocytes counted
Nos of micronucleated 
normocytes/1000 polychromatic 
erythrocytes counted in the 
same field
Control 0 4 None
Pindolol 25 5 ti
50 6 tt
100 - (Died) it
Positive
control 3.5 32
tt
Results are Means for four animals
DISCUSSION
Many short-term tests have been developed for the screening of carcinogens 
as mutagens but by far the most rapid and economical methods are the Ames’ 
bacterial and mammalian micronucleus tests -which have been used in this 
study•
The absence of positive effects in the Ames test, (2-3 fold and dose- 
dependent increases in His* revertant colonies) by any of the beta-adrenergic 
blocking agents, in the presence or absence of S-9 mix, suggests that neither 
the parent compounds nor their hepatic metabolites (produced by S-9 mix in 
vitro) caused any changes in the genetic structure of the Salmonella typhi- 
aturium strains either by frame-shift or base-substitution mutations. Hie 
bacteriocidal action on strains TA100 and TA1537 by propranolol and strains 
TA9 8, TA100 and TA1537 by oxprenolol at concentration of 1000ug/plate, in the 
absence of S-9 mix and its absence in the presence of s-9 mix, suggests that 
oxprenolol and propranolol are metabolized to products non-toxic to the 
bacterial strains. Some beta-adrenergic blocking agents undergo gastro­
intestinal metabolism (Meier, 1978) and so the use of gastrointestinal mucosal 
homogenate would be of interest, but the problem of obtaining a sterile and 
active homogenate is enormous in view of the large numbers of bacteria present 
in the gastrointestinal tract.
The fact that there was no marked increases in the number of micronuclei 
above the spontaneous level by seven out of nine of the beta-adrenergic 
blocking agents studied as compared to the positive control, mitomycin c, 
indicates that neither the parent compounds nor their metabolites had any 
effect on the bone-marrow cells in the mouse. The increases in the numbers of 
micronuclei above the spontaneous level for propranolol (2-fold) and oxprenolol
(3-fold) at the highest dose levels suggest possible chromosomal damage 
to the borte-marrow cells by either the parent drugs or their metabolic 
products* However, these are below the 4-5 fold increase suggested by 
Heddle and Bruce (1977) to describe a positive effect in the micronucleus 
test*
The bacteriocidal action of propranolol and oxprenolol on the His*, revertant 
colonies in the absence of 5-9 mix in the Ames test and their increases in 
the number of micronuclei above the spontaneous level in the raicronucleus 
test, suggests that their action is at the chromosomal level* This indicates 
the possibility of the chromosomal damage being caused by the parent compounds 
rather than their metabolic products* However the epoxidation of the allyloxy 
side-group of oxprenolol in the mice jln vivo, leading to the production of 
reactive metabolites cannot be overruled* The combined result of Ames and 
micronucleus tests, for all the beta-adrenergic blocking agents, confirms 
the suggestion that the two tests complement each , other and together provide 
a more sensitive short-term test system of higher predictive value as 
suggested by Jenssen and Hamel (1980).
These results suggest that none of the beta-adrenergic blocking agents
studied, with the possible exception of oxprenolol and propranolol, may show
*
properties characteristic of chemical mutagens although the levels of the.effect 
Oxprenolol and propranolol
of/ on the bone-marrov cells in mice, at the chromosomal level, are far 
below that shown by known chemical mutagens such as mitomycin c* However, it 
must be borne in mind that, the dosage of mitomycin c used in this study is 
far below its sub-acute level which is the level represented by the highest 
dose levels of the beta-adrenergic blocking agents used.
CHAPTER FOUR
EFFECT OF SOME BETA-ADRENERGIC BLOCKING AGENTS ON RAT 
GASTROINTESTINAL MUCUS GLYCOPROTEIN SYNTHESIS
INTRODUCTION
Gastrointestinal Mucus
Gastrointestinal mucus is secreted by the cells of the surface epithelium 
and those lining the crypts of the mucosa and pyloric glands. It is highly 
alkaline and viscous, covering the surface of the mucosa with a tenacious 
layer about 1mm thick.
It is firmly established that the molecules responsible for the viscous 
and gel-forming properties of mucus are glycoproteins (Spiro, 1970; Allen 
et al, 1976). Mucus glycoproteins are characterized by a high carbohydrate 
to protein ratio, the carbohydrate constituting usually more than 65% of the 
dry weight (Schrager and Oates), 1971; Allen and Snary, 1972; Jabbal et al, • 
19765 Gold and Miller, 1974; Marshall and Allen, 1977). This distinguishes 
them from many other glycoprotein secretions in the gastrointestinal mucus 
glycoproteins.
Mucus glycoproteins from all regions of the gastrointestinal tract have a 
very high molecular weight and consists of a large number of carbohydrate 
side chains attached to a protein core. The carbohydrate chains may contain 
up to five different monosaccharides; namely galactose, fucose, N-acetyl- 
glucosaraine, N-acetylgalactosamine, and sialic acid, distinguished as either 
N-acetyl - or N-glycolyll-neuraminic acid. Trace quantities only of mannose 
and glucose have been reported for purified gastrointestinal mucus glycoproteins 
The size of carbohydrate side chains and relative amounts of the different 
sugars are very variable in different gastrointestinal mucus glycoproteins 
(Schrager and Oates, 1971; Allen and Snary, 1972; Jabbal jet al^ 1976; Gold 
and Miller, 1974; Marshall and Allen, 1977).
The sequence of the sugar residues and the type of glycosidic linkage between
them are determined genetically by the expression of specific 
glycosyltransferase enzymes which catalyse the step-wise addition of 
sugar residues to the growing chain during glycoprotein biosynthesis 
(Vatkins, 1972).
Sialic acid and ester sulphate, often together, are commonly found in 
glycoproteins from gastrointestinal mucus. Sialic acid residues are 
always terminal whereas ester sulphates residues occur in a more internal 
position within the sugar chains of the glycoprotein. Both sialic acid 
and ester sulphate have pKa values of less than 3« Thus any terminal N- 
acetylneuraminic acid residue will mean a strongly negatively charged molecule. 
The function of this negatively charged residue is not entirely clear; 
although at least in some conditions, it is important in determining the 
tertiary structure of the glycoprotein. At low ionic strengths, when there 
is little charge shielding by counter ions, there will be increased repulsion 
between these negatively charged residues on adjacent carbohydrate chains 
resulting in an expansion of the tertiary structure of the molecule and a 
rise in its viscous properties. This is a feature of pig gastric mucus and 
rat intestinal mucus glycoproteins (Forstner et al, 1973a).
The linkage of the carbohydrate side chains to the central protein core
is the same for all glycoproteins from gastrointestinal mucus. N-
acetylgalactosamine is linked from the carbon at position one (the potential
serine
reducing group) to the hydroxyl groups of either [or threonine in the protein 
chain. This is reflected in the threonine and serine content of these 
gastrointestinal mucus glycoproteins which is considerably higher than other 
proteins (Schrager and Oates, 1971; Scawen and Allen, 1977; Jabbal ejt al_, 1976)
A high proline content is also found in these gastrointestinal mucus 
glycoproteins, with-smaller amounts of other amino acids, notably alanine, 
glycine, glutamic and aspartic acids (Schrager and Oates, 1971; Scawen and
Allen, 1977; Jabbal et al, 1976). Presumably, this large number of 
proline residues in the protein gives the necessary conformation for the 
sort of close packing of carbohydrate chains found in the glycoproteins.
Biosynthesis of Glycoprotein
It has been concluded from studies using classical inhibitors of protein 
synthesis (Spiro and Spiro, 1966) and from the autoradiographies1 demonstration 
of localization of growing polypeptide chains around the polysomes (Neutra 
and Leblond, 1966) that biosynthesis of the protein fraction of the glyco­
protein takes place before and occurs independently of carbohydrate attachment. 
Once incorporated into the polypeptide chains of mucus glycoproteins, the 
amino acids serine and threonine may be glycosylated.
The addition of the first carbohydrate unit to the peptide chains and 
subsequent elongation of the carbohydrate chain is affected by a group of 
the enzymes known as the glycosyl transferases. These enzymes catalyse the 
transfer of sugar residues from sugar nucleotide donors (UDP-galactose, 
UDP-N-acetylglucosamine, UDP-N-acetylgalactosaraine, CMP-N-acetylneurarainic 
acid and GDP-fucose) to the polypeptide or growing carbohydrate chains as 
the glycoprotein moves from the rough endoplasmic reticulum and Golgi complex. 
Evidence exists that glycosylation may occur even before the polypeptide 
chain has left the ribosome (Lawford and Schachter, 1967; Louisot et al, 1967).
It has been suggested that subcellular distribution of the glycosyl trans­
ferases could play a role in the control of glycoprotein synthesis (Schachter,
1974). Thus the localization of N-acetylneurarainyl transferase in the Golgi 
complex could preclude N-acetylneuraminic acid from appearing in the carbo­
hydrate chain anywhere other than in terminal positions (Schachter ejt ajL, 1970)
The Effects of Drugs on Mucus Production
Drugs may alter the rate of secretion of mucus, the chemical and physical
structure of mucus or its rate of synthesis. They may thus affect the 
normal physiological functions of mucus and its protective effect on the 
epithelium resulting in therapeutic benefit or adverse drug.reactions. The 
sites of action of drugs on mucus may be central-via the hypothalamus or 
pituitary-adrenal axis, systemic-involving catecholamines or other hormonal 
control, or topical to the mucus-producing cell.
Phenylbutazone results in reduced synthesis of sulphated glycoproteins as 
determined by the rate of incorporation of labelled sulphate by rat gast‘c 
mucosa (Lambert et al, 19&7) and asprin produces the same effect in dogs 
(Lev et jQ, 1972)• Mucus secreted by dogs after treatment with asprin 
cortisone, corticotropin (ACTH) phenylbutazone or iodomethacin contained 
much less carbohydrate and was much more rapidly digested by pepsin than was 
control mucus (Menguy and Desbaillets, 1968), possibly because of the 
inhibitory action of these drugs on glucosamine synthetase (glucosamine 
phosphate isomerase) (Peery, 1968). In contrast the gastric-ulcer healing 
drug carbenoxolone causes the production of increased amounts of a carbohydrate- 
rich tenacious mucus both in human patients and experimental animals (Parke 
and Symons, 1977)•
Most corticosteriods and anti-inflararaatory drugs tend to cause gastrointestinal
inflammation, associated with impaired mucus production, erosions of the
*
mucosa and haemorrhage. These adverse effects occur in many different 
animal species and are produced by the following drugs in order of 
increasing gastrointestinal toxicity: salicylate < oxyphenbutazone < 
asprin < phenylbutazone <dichlofena < indomethacin (Menasse-Gdynia and 
Drupp, 197^)* The mechanism of gastrointestinal inflammations (impairment of 
mucus synthesis and loss of intergrity of the gastric mucus barrier) has been 
studied most extensively with asprin, a drug which clinical studies have
shown to be a major causative agent of gastric and duodenal ulcers 
(Rainsford, 1975)- Dekanski et al, (1975) have shown that asprin 
administered orally to rats results in significant reduction in the rate 
of gastric mucus synthesis, as measured by the incorporation of N-acetyl 
glucosamine, in those animals exhibiting gastric erosions. Aspirin has 
no significant effect on the individual hexose, hexosaraine, fucose and 
sialic acid contents of glycoprotein, although there are significant 
differences in these carbohydrates between those asprin-treated rats that 
show erosions and those that do not.
Asprin stimulates the adenylate cyclase activity of rat gastric mucosa 
although the converse might have been expected (Mangla et al, 1974), but it 
is an inhibitor of prostaglandin synthetase and could exert its action on 
the gastric mucus synthesis by lowering endogenous prostaglandin activity 
(Rainsford, 1975)* Kent and Allen (1968) demonstrated that salicylate
glycoprotein synthesized by sheep colon and human stomach and Lukie and 
Forstner (1972) further demonstrated the inhibitory action of salicylate 
on mucus glycoprotein of rat small intestine by its reduction of the rates
Similar studies of the effects of indomethacin, phenylbutazone and steroid 
diuretic spironolactone on the synthesis of gastric mucus have been carried 
out in the rat and ferret (Shillingford, 1975? Dekanski et al, 1975)- Th«
into rat mucosal glycoprotein were inhibited by administration of each of 
these drugs. Asprin and phenylbutazone also diminished the hexose content 
of the gastric mucus glycoprotein from which it may be inferred that these
inhibited glucose and threonine into
rates of incorporation of both N-acetyl P H  glucosamine and galactose
drugs inhibit the synthesis of mucus glycoprotein by impairment of glycosylatibn
The drug carbenoxolone which has proved to be a useful treatment for 
healing gastric and duodenal ulcers has been shown to enhance the synthesis 
of mucus both in human patients and experimental animals (Johnston jet al,
1975)y and markedly enhances the rates of incorporation of a number of 
radioactively labelled monosaccharides into gastric mucosal glycoprotein. 
These effects were not seen with preparations of duodenal mucosa, however. 
Similar incorporation studies with N  threonine, [3H] serine, [3h] proline 
and [3h] asparagine have shown that carbenoxolone pretreatment of either rats 
or ferrets does not lead to any increased rate of amino acid incorporateon into 
gastric glycoprotein and hence does not increase the rate of synthesis of 
the polypeptide precursor of the mucus glycoproteins. Carbenoxolone also 
increases the content of fucose and sialic acid and the activities of UDP« 
glucoronosyltransferase of the gastric mucosa but, again, the intestinal 
mucosa is unaffected by the drug. The increased fucose and sialic acid 
contents are indicative of increased glycoprotein and mucus synthesis. The 
increased UDP-glirctsronosyl transferases are probably related to the mechanism 
of absorption of the drug from the stomach since glucuronic acid is not a 
normal constituent of gastric mucus, although Hietenan (1975) ha® shown that 
administration of salicylate to rats causes a marked reduction in the UDP- 
glucuronosyl transferase of both the gastric and duodenal mucosae.
It has consequently been suggested that the mode of action of carbenoxolone 
is to enchance the synthesis of gastric mucus by increasing the activities 
of the microsomal glycosyltransferases and thereby to increase the protection 
of the gastric mucosa against the corrosive actions of acid, pepsin and bile. 
There are, however, other suggested mechanisms of the ulcerhealing action of 
carbenoxolone (Avery-Jones and Parke, 1975)* Amer et fil^, (197^) demonstrated 
that carbenoxolone inhibited 3* 5' cyclic AMP phosphodiesterase activity in
gastric mucosa and other tissues of the rat and other species. Peskar and 
Peskar (1976) have also shown that this drug inhibits gastric prostaglandin 
dehydrogenase and A -1 3 reductase, enzymes which deactivate the prostaglandins.
Drugs not generally associated with diseases of epithehal tissues or 
abnormalities of mucus secretion may nevertheless have an effect on mucus.
This is particularly likely with drugs that affect cellular metabolism, such 
as adrenaline and other beta-adrenergic agents,beta-adrenergic blocking 
agents, inhibitors of adenylate cyclase or phosphodiesterase, prostaglandins 
and so on, and Forstner et al^  (1973) have shown that beta-adrenergic agents, 
theophylline and dibutyryl cyclic AMP all stimulate glycoprotein synthesis in 
intestinal slices.
The site of mucus glycoprotein synthesis isthe endoplasmic reticulum of the 
cell, which is also the location of enzymes concerned in drug metabolism and 
deactivation and in metabolic activation of carcinogens. The highly reactive 
metabolites of these carcinogens undoubtedly damage the endoplasmic reticulum 
in some way, impairing and changing the biosynthesis of mucus and other 
glycoproteins concerned in the characterization of the cell surface and in 
immune surveillance (Parke, 1977$)- Such changes in glycoprotein synthesis may 
thus explain many of the biological anachronisms of cancer such as the rapid 
cell growth and division; the immune escape mechanisms and the synthesis of 
fetal protein. These changes'ini; the endoplasmic reticulum may explain the 
observed correlations between changes in the nature of the plasma membrane 
glycoproteins of mucosal epithelial cells; changes in mucus synthesis and 
malignancy (Parke and Symons, 1977)- Drugs that affect glycoprotein synthesis 
may, therefore, like anti-hormones eventually have a role in the treatment 
of epithelial cancer.
The beta-adrenergic blocking agent, practolol, has been shown to cause
ulceration of the cornea of the eye, nasal and oral mucosa (Wright, 1975?
Rahi et al, 1976) as well as psoriasiform changes in the skin (Felix and 
Ive, 1974) in patients on long-term treatment, known as oculomucocutaneous 
syndrone. However, it is not known whether the practolol reaction is specifi 
to practolol or is the direct specific effect of pharmacologically induced 
changes by beta-blockade (Gaylarde and Sarkany, 1975)* There have been few 
convincing reports of the oculomucocutaneous reactions with oxprenolol (Holt 
and Waddington, 1975» Knapp et al, 1975) and one with propranolol (Cubey and 
Taylor, 1975) but these are very rare.
Recent observations in patients on long-term treatment with practolol 
indicates that it causes sclerosing peritonitis leading to intestinal 
adhesion and obstruction (Nicholls, 1976). This has led to the suggestion 
that practolol might be inhibiting the synthesis of gastrointestinal or 
peritoneal mucus which are essential for the lubrication and free movement
j
of the gastrointestinal tract respectively.
Investigations were therefore carried out on the effects of administration 
of practolol and other beta-adrenergic blocking agents on the incorporation 
of radiolabelled sugar and amino acid precursors into rat gastrointestinal 
mucus glycoproteins to ascertain whether the adverse effects shown by 
practolol are peculiar to it or are a direct pharmacological result of 
beta-blockade, and thus to establish the possible mechanisms of its potential 
toxicity.
EXPERIMENTAL
Materials
Soluene-350 tissue solubilizer and dimilume-3 0 phosphor mixture were 
purchased from Packard Instrument Co, Reading, England,
N-Acetyl-D- glucosamine, D-[i-^hJ fucose, -and N  -hexadecane
standards and N-acetyl [4,5,6,7,8,9-14c] neuraminic acid were obtained from 
The Radiochemical Centre, Amersham, U.K, L- [g-3h] Serine was purchased from 
New England Nuclear, Boston, USA, All other chemicals were obtained in the 
purest possible forms from British Drug Houses (BDH) Chemicals Ltdf Poole, 
England.
Animals
Male Wistar albino rats (l40-l60g) were kept in cages in groups of six or 
less and fed ad libitum on Spratt's laboratory chow. Test animals received 
oral doses of the drugs (lml/lOOg body wt) and controls received equivalent 
amount of drug vehicle, water in case of propranolol, pronethalol and acebutolo 
and 0.1M citric acid/Na^HPO^ buffer pH6.5 for atenolol and practolol. Animals 
were killed by cervical dislocation and stomach and intestine (15cm from 
stomach) removed immediately for preparation of mucosal homogenates.
Treatment of Animals
Two separate animal treatments were performed:
a) Administration of varying dose levels of drugs (5-200mg/kg/day)
for 5 days and killing 15 hours after last dose (Tables 4.1-4.5* 4.10, 
4.11).
b) Administration of fixed dose levels of drugs (l50mg/kg/day) for 5 days 
and killing 5 hours after last dose. (Tables 4.6~4.10).
Mucosal Homogenate Preparation
The stomach and intestine were cut open along the greater curvature and 
longitudinally respectively, and the contents washed with chilled 1*15$ 
KCl(w/v) solution* The washed stomach/intestine were kept in ice-cold 
0*9$ NaCl(w/v)* The mucosae of the glandular area were scraped on a glass 
plate (25cm x 25cm) with a microscope slide and put into 10ml modified version 
of Krebs-Ringer bicarbonate solution (NaCl, 119®M; KC1, 5*6mM; CaCl , 3«0raM; 
KH^PO^, 1.4mM; MgSO^, 1.4raM; NaHCO^, 29*3®M; L-glutamine, 8*0mM). This was 
homogenized at 4°C in Potter-Elvehjem homogenized with teflon pestle to 
give a homogenous suspension*
Assay of Glycoprotein Synthesis
Duplicate samples (4ml each) of mucosal homogenate were pipetted into
o10ml stoppered tubes. These were preincubated for 5 minutes at 37 C and 
radiolabelled precursors (10-40 jul) added (as shown), shaken and incubated 
for a further 1-3 hours in a shaking water incubator (100 cycles/rain). The 
medium was gassed with 95$ 0 : 5$ CO every 20 minutes.
The reaction was terminated with 5ml trichloroacetic acidjphosphotungstic 
acid 20$(w/v) : 2$(w/v) and the tubes kept at 4°C overnight. The precipitate 
formed was spun down in a Mistral 6L centrifuge and washed twice with 5®i 
each of distilled water and twice with 5^1 each of chloroforms methanol 
(1:1 v/v).
.  .  oThe tubes and contents were air-dried at 37 C overnight and cooled to room
temperature. The glycoprotein was transferred into pre-weighed glass vials
and reweighed. Distilled water (200 nl) and soluene -350 (lral) were added.
oThe vials were capped and allowed to stand overnight in an oven at 50 C to 
speed up the solubilization process.
Radiolabelled precursors and quantities used in experiments
Radiolabelled
Precursor
Specific activity 
(Ci/mmol)
Volume used 
( -ul)
Quantity used 
(ng)
N-Acetyl-D-Q-^Hj glucosamine 3 *0 ,  4 .7 + 25, 40+ 72 .5
D- {i-^hJ Fucose 3-9 12.5 20 .8
N - A c e t y l - [ 4 , 5 , 6 , 7 , 8 , 9 - l4 c ]  
neuraminic acid 0 .245 10 .0 323 .4
L-(g-3h] Serine 1 .8 2 5 .0 6 0 .0
+ used where shown in tables
They were allowed to cool to room temperature before addition of 10ml 
dirailume-30 phosphor mixture and shaken for thorough mixing. The radio­
activity in the glycoprotein was measured by LKB Wallac ultrabeta 2002 
scintillation counter programmed for dpm calculations based on internal 
standard channel efficiency determination.
Experimental blanks were prepared by adding the trichloroacetic acid: 
phosphotungstic acid, immediately after addition of radiolabelled precursors, 
to mucosal homogenate.
Quench Curve Preparation
Quench curves were prepared for M  -and - hexadecane standards to
enable direct conversion of cpm to dpm based on internal standard efficiency 
ratio (Fig. 4.1).
The samples for the quench curves contained the following:-
Dimilume-30 phosphor mixture - 10ml
Soluene-350 “ 1®!
Water - 0.2ml
Chloroform as quencher - (0-0.5) **»1
Ph] -or E 4ql -Hexadecane standard - 10 jul
RESULTS
Linearity -: of Incorporation of Radiolabelled Precursors into Rat 
Gastrointestinal Mucus Glycoprotein
The incorporation of radiolabelled precursors into rat gastrointestinal 
mucus glycoproteins at varying periods of incubation and concentration 
of radiolabelled precursors shoved a linearity in respect of both the 
incorporation with time of N-acetyl glucosamine, D-fucose and L-serine and 
of concentration for L-serine (Pigs. 4.2 - 4.5)*
Rates of Incorporation of Radiolabelled Precursors into Rat Gastrointestinal 
Mucus Glycoproteins After Pretreatment vith Beta-adrenergic Blocking Agents
Pretreatment of rats with varying concentrations of beta-adrenergic blocking . 
agents (5 0, 100, 150* 200 mg/kg) gave rise to changes in the rates of 
incorporation of radiolabelled precursors into gastrointestinal mucus 
glycoproteins. However the rate of incorporation was not significantly 
affected by the time of killing of animals. At the dose levels.of 100, 150 
and 200mg/kg, pronethalol stimulated the rate of incorporation of N-acetyl- 
glucosamine into rat gastric mucus glycoprotein whilst propranolol stimulated 
it at the dose levels of 150 and 200 rag/kg, without significant effects on 
the rates of incorporation of D-fucose, N-acetylneuraminic acid and L-serine. 
Acebutolol on the otherhand significantly enhanced the rate of incorporation 
of L-serine into gastric mucus glycoprotein at the dose level of 150mg/kg 
without significant effects on the rates of incorporation of N-acetylglucosamine, 
D-fucose and N-acetylneuraminic acid. (Tables 4.1 - 4.3, 4.6 - 4.8).
Atenolol showed some inhibition in the rate of incorporation of all the 
radiolabelled precursors into gastric mucus glycoprotein with the exception
of the stimulation shown for D-fucose at the dose level of 150mg/kg whilst 
practolol inhibited significantly the rates of incorporation of all the 
radiolabelled precursors at all four dose levels (50, 100, 150, 200mg/kg) 
into gastrointestinal mucus glycoprotein (Tables 4.4, 4.5, 4.9-4.11).
However pretreatraent with lower dose levels of practolol (5, 10, 20mg/kg) 
did not significantly alter the rates of incorporation of N-acetylglucosaraine 
and D-fucose into gastrointestinal mucus glycoproteins (Tables 4.5, 4.10,
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Table 4,1 . Effect of Administration of Pronethalol on Rate of
Incorporation of N-acetylglucosamine into Rat 
Gastric Mucosal Glycorproteins
Glycoprotein Synthesis
Treatment Dose(mg/kg) •13Mole x 10 N-acetylglucosamine/ 
mg glycoprotein/hr
% of control 
value
Control 0 10.1 + 0.8 (6) 100
Pronethalol 50 11.1 + 0.9 (4) 110
100 15*7 + 1*0 (6)* 155
200 16.5 + 1.8 (6)* 163
Results are Mean + SEM of duplicate samples for number of animals given in 
parenthesis*
Value significantly different from control; *P<0.01
Table 4.2 Effect of Administration of Propranolol on Rate of
Incorporation of N-acetylglucosamine into Rat
Gastric Mucosal Glycoprotein
Glycoprotein Synthesis
Treatment. Dose(ag/kg)
“13Mole x 10 N-acetylglucosamine/ 
mg glycoprotein/hr
% of control 
value
Control 0 10.5 + 0.9 (5) 100
Propranolol 50 11.2 + 1.2 (6) 107
100 11.0 + 1.6 (4) 105
200 13.5 ♦ 0.5 (6)* 129
Results are Mean + SEM of duplicate samples for number of animals given in 
parenthesis.
Value significantly different from control; *P <0.02
Table 4.3 Effect of Administration of Acebutolol on Rate of
Incorporation of N-acetylglucosamine into Rat 
Gastric Mucosal Glycoproteins
Glycoprotein Synthesi s
Treatment Dose(mg/kg) —13Mole x 10 N-acetylglucosamine/ 
mg glycoprotein/hr
% of control 
value
Control 0 7.0 + 0.7 (6) 100
Acebutolol 50 6.9 + 1.0 (4) 99
100 7.1 + 0.6 (6) 101
200 7.7 + 0.6 (6) 110
Results are Mean + SEM of duplicate samples for number of animals given 
in parenthesis.
Table 4.4 Effect of Administration of Atenolol on Rate of
Incorporation of N-acetylglucosamine into Rat
Gastric Mucosal Glycoproteins
Glycoprotein Synthesis
Treatment Dose(mg/kg) <■•13Mole x 10 N-acetylglucosaiaine/ 
mg glycoprotein/hr
% of control 
value
Control " 0 9.8 + 1.4 (4) 100
Atenolol 50 7.9 + 1.5 (3) 81
100 7.1 + 0.9 (3) 72
200 8.6 + 0.9 (3) 88
Results are Mean + SEM of duplicate samples for number of animals given 
in parenthesis
Table 4.5 Effect of Administration of Practolol on Rate of
Incorporation of N-acetylglucosamine into Rat 
Gastric Mucosal Glycoprotein
Treatment Dose(mg/kg)
Glycoprotein Synthesi s
-13Mole x 10 N-acetylglucosamine/ 
rag glycoprotein/hr
% of control 
value
Control 0 3.5 ♦ 0.1 (3)
+
100
Practolol 5 3.3 + 0.4 (3) 94
10 3.2 + 0.2 (3) 91
20 3.5 + 0.1 (3) 100
Control 0 14.0 + 1.2 (6) 100
Practolol 50 9.6 + 0.9 (5)* 69
100 6.5 + 0.7 (6)*** 46
200 8.0 + 0.7 (6)** 57
Results are Mean + SEM of duplicate samples for number of animals given in 
parenthesis.
Value significantly different from control; *P<0.05, **P<0.01, ***P<0.001
Different control values are due to the use of N-acetyl-D- [x-3h] glucosamine 
with different specific activities (+Refer to table of radiolabelled precursors)
Table 4.6 Effect of Administration of Acebutolol on Rate of
Incorporation of Radiolabelled Precursors into Rat
Gastric Mucosal Glycoproteins
Glycoprotein Synthesis
Radiolabelled
Precursor Mole x 10-15 radiolabelled precursor/ 
mg glycoprotein/hr
% of control 
value
Control Test
"^N-Acetyl-D- 
[l-3H] glyco- 
samine
304 + 42 (4) 378 + 36 (4) 124
D- [1-^ h ] Fucose 6 .9 + 0.7(6) 6 .5 + 0.5(6) 94
N-Acetyl Jj 4,5» 
6,7,8,9-*c]
neuraminic acid
4.5 + 0.5(4) 5.0 + 0.3(4) 111
L- [g-3hJ Serine 16.8 t 3.0(4) 26 .9 + 2.5(5)* 160
Dose: 150 mg/kg/day for 5 days
Results are Mean + SEM of duplicate samples for number of animals given 
in parenthesis.
Value significantly different from control; *P<0.05 
1 Refer to table of radiolabelled precursors.
Table 4.7 Effect of Administration of Propranolol on Rate of
Incorporation of Radiolabelled Precursors into Rat
Gastric Mucosal Glycoprotein
Radiolabelled
Glycoprotein Synthesis
Precursor Mole x 10~*3 radiolabelled precursor/ 
mg glycoprotein/hr % of control value
Control Test
N-Acetyl-D- 
[l- H]glyco- 
samine
304 + 42 (4) 390 + 60 (4) 128
D- [l-.^H|Fucose 6.9 + 0.7 (6) 5.8 + 0.5 (6) 84
N-Acetyl ,£4 ,5 , 
6,7,8,9- C] 
neuraminic acid
4.5 + 0.5 (4) 5.2 + 0.6 (4) 116
L- [g-3h] Serine . 16.8 + 3.0 (4) 16.7 + 1.5 (5) 99
Dose - 150mg/kg/day for 5 days
Resutls are Mean + SEM of duplicate samples for number of animals given 
in parenthesis.
*1* Refer to table of radiolabel led, precursors.
Table 4*8 Effect of Administration of Pronethalol on Rate of
Incorporation of Radiolabelled Precursors into Rat 
Gastric Mucosal Glycoproteins
Glycoprotein Synthesis
Radiolabelled
Precursor
Mole x lo”*'* radiolabelled precursor/ 
mg glycoprotein/hr % of control
Control Test
value
*N-Acetyl-D- 
[l- h J gluco­
samine
304 + 42 (4) 425 + 89 (4) 140
D- [i-3h] Fucose 6 .9 + 0.7 (6) 6 .3 + 0 .4  (6) 91
N-Acetyl [*4,5,6, 
7,8,9, cj
neuraminic acid
4.5 + 0.5 (4) 3.6 + 0.5 (4) 80
L- [g-^hJ Serine 19 .8 + 2 .0 (4) 2 1 .1 + 1 .5 (4) 107
Dose:- 150 mg/kg/day for 5 days
Results are Mean + SEM of duplicate samples for number of animals given in 
parenthesis. ~
Refer to table of radiolabelled precursors.
Table 4.9 Effect of Administration of Atenolol on Rate of
Incorporation of Radiolabelled Precursors into RatA - - -       . . —   .       . . - ...--
Gastric Mucosal Glycoproteins
Glycoprotein Synthesis
Radiolabelled
Precursor
Mole x 10-15 radiolabelled precursor/ 
rag glycoprotein/hr % of control
« Control Test
value
N-Acetyl-D-[l-3H]
glucosamine
974 + 141 (4) 880 + 94 (4) 90
D- Q — 3h] Fucose 4.5 + 0.1 (5) 5-9 + 0.4 (4)* 131
N-Acetyl[4,5,6,7, 
8,9- c]
neuraminic acid
11.1 + 2.5 (4) 6.4 ± 0.9 (4) 58
L- [g-^hJ Serine 46.6-+ 3.9 (5) 37.1 + 3.7 (5) 80
Doses- 150 mg/kg/day for 5 days
Results are Mean + SEM of duplicate samples for number of animals given in 
parenthesis.
Value significantly different from control; *P<0.01
Table 4.10 Effect of Administration of Practolol on Rate of
Incorporation of Radiolabelled Precursors Into Rat
Gastric Mucosal Glycoproteins
Glycoprotein Synthesis
Radiolabelled
Precursor
Dose
(mg/kg)
Mole x 10""^^radiolabelled 
precursor/mg glycoprotein/hr
% of 
control 
valueControl Test
N-Acetyl-D- [i«3h] 
glucosamine 150 IO85 + 164 (4) 746 + 57 (4) 69
D- [i-^h] Fucose 5 5.2 + 0.2(4) 88
10 5.9 + 0.4(4) 5-5 + 0.2(4) 93
20 5.1 + 0.4(4) 86
150 9.4 + 1.4 (5) 5.7 + 0.4(5)* 61
N-Acetyl |jt,5,6,
7 ,8 ,9- C]
neuraminic acid
150 11.1 + 2.5(4) 4.7 + 0.3(4)* 42
L- jG-^iiJserine 150 46.6 + 3 .9 (5 ) 2 9 .8 + 3-6(5)* 64
Results are Mean + SEM of duplicate samples for number of animals given 
in parenthesis.
Value significantly different from control; *P<0.05
Table 4.11 Effect of Administration of Practolol on Rate of
Incorporation of Radiolabelled Precursors into Rat 
Intestinal Mucosal Glycoproteins
Glycoprotein Synthesis
Radiolabelled
Precursor
Dose
(mg/kg)
Mole x 10 ^radiolabelled precursor/ 
mg glycoprotein/hr
% of 
control 
value
Control Test
N-Acetyl-D- [i-^h ] 
glucosamine 150 511 + 86 (4) 452 + 51 (4) 88
Q- Fucose 5 4.6 + 0.2(4) 92
10 5 .0 + 0.8(4) 4.9 + 0.2(4) 98
20 4.9 + 0.3(4) 98
150 6.3 + 0.9(4) 4.1 + 0.3(4) 65
L- [g-^hJ Serine 150
•
4.9 + 0.6(4) 3.7 + 0.5(4) 76
Results are Mean + 
in parenthesis.
SEM of duplicate samples for number of animals given
DISCUSSION
Recent evidence has suggested the involvement of cyclic nucleotides in 
gastrointestinal function (Kiraberg, 1974$ Eichhom et al, 1974). The 
possibility of the mediation of cyclic AMP and cyclic GMP in.rat gastric 
mucus glycoprotein synthesis has been investigated,and Macdonald «*t aJ (1977) 
have shown that the inhibitory effect on glycoprotein synthesis on pre­
incubation of rat gastric mucosal scrapings with dibutyryl cyclic AMP(10 S*) 
in vitro was nullified at lower concentrations indicating on optimum 
requirement for cyclic AMP for an inhibitory effect to be shown. Beta- 
adrenergic blocking agents, by their probable effects on cyclic nucleotide 
levels may of consequence affect glycoprotein synthesis.
It appears from the results in this study that practolol and atenolol by 
their inhibition of glycoprotein synthesis, measured by the effects on 
rates of incorporation of radiolabelled amino acid and sugar precursors into 
rat gastrointestinal mucus glycoprotein, behaved in a way dissimilar to 
pronethalol, propranolol and acebutolol which stimulated the synthesis of 
mucus glycoproteins. These findings cannot be explained by the direct 
pharmacological result of beta-blockade, since if it were so all the beta- 
adrenergic blocking agents must act in a similar fashion. This is further 
supported by the fact that the expected probable decrease in cyclic nucleotide 
levels as a result of beta-blockade should be reflected in a probable decrease 
in glycoprotein synthesis (Solderling e*t a^ L, 1973; Hepp, 1972) which was only' 
shown by practolol and to some extent by atenolol but not pronethalol, 
acebutolol and propranolol.
The pharmacokinetic properties of these compounds which are a reflection
chain
of their characteristic ring structure and side/if any, other than the 
isopropylarainopropoxy side chain (Fig 1.1) responsible for their beta-
blockade effect, may explain the observed differences in their effects 
on glycoprotein synthesis, Atenolol, practolol and acebutolol have similar 
structural characteristics so the differences in their effects on glyco­
protein synthesis may be explained by differences in gastrointestinal 
absorption and metabolism (Kiechel and Meier, 1978) probably as a result 
of side chain structural differences* The stimulation in glycoprotein 
synthesis shown by propranolol and pronethalol may be a result of their 
naphthalene ring structure* However, the different degrees of their effect 
may be due to the extensive Mfirst-passn effect shown by propranolol as 
opposed to pronethalol (Bond and Howe, 1967; Kiechel and Meier, 1978)*
The incorporation of the amino acid serine into gastrointestinal mucus 
glycoprotein is a measure of protein synthesis whilst the incorporation of 
the sugars; fucose, N-acetylglucosamine and N-acetylneuraminic acid, are a 
measure of glycosylation of proteins. The marked inhibition of glycoprotein 
synthesis by practolol may be explained in two ways. Firstly, by its 
inhibition of protein synthesis,.less protein may be available for glyco­
sylation suggesting that the inhibition of glycosylation is a direct resultr 
of inhibition of protein synthesis. Alternatively, it may be affecting protein 
synthesis and glycosylation separately. The latter may explain the observed 
inhibition of glycoprotein synthesis by atenolol since by its inhibitory and 
stimulatory effects on the rates of incorporation of serine and fucose 
respectively into gastric mucus glycoprotein,appears to indicate that protein 
synthesis is not the rate limiting 3tep to glycosylation. The effect of 
propranolol and pronethalol on glycoprotein synthesis is probably at the 
glycosylation level without any effect on protein synthesis. However, 
acebutolol appears to stimulate protein synthesis without significantly 
affecting glycosylation.
Whereas the changes observed with pronethalol and propranolol on the rate 
of incorporation of N-acetylglucosamine into gastric mucus glycoprotein 
appears to be dose-dependent, those shown by practolol, atenolol and 
acebutolol are not directly dose—dependent. Acebutolol and atenolol, at 
the dose levels of $0, 100, 150 and 200 mg/kg did not have much significant 
effect on gastric mucus glycoprotein synthesis. However, the significantly 
marked inhibition of gastrointestinal mucus glycoprotein synthesis by 
practolol at these dose levels may probably be a result of a reaction in 
response to practolol on prolonged high dosage which appears to be in 
favour of the immunological basis for the adverse side—effects shown by 
practolol in man (Behan et al, 1976). The fact that lower dose levels of 
practolol (5i 10, 20 mg/kg) did not significantly inhibit the rates of 
incorporation of N-acctylglucosamine and D-fucose into gastrointestinal 
mucus glycoproteins, suggest a possible threshold dose, which is above 
the normal human dosage (-^mg/kg), for practolol to show its inhibitory 
effects on glycoprotein synthesis.
Another possible cause of the inhibition of mucus glycoprotein synthesis 
by practolol and to some extent atenolol may be the degranulation of the 
mucosal cell endoplasmic reticulum as has been suggested for chemical 
carcinogens (Delaunay and Schapira, 197^5 Parke, 1977b). However, against 
this background is the finding that atenolol and practolol did not enhance 
rat hepatic microsomal biphenyl 2-hydroxylase and ethoxyresorufin 0- 
deethylase activities which are catalysed by cytochrome P-448 thought to 
be formed by chemical carcinogens probably through degranulation of the 
endoplasmic reticulum (Parke, 1977a; Burke and Mayer, 1975)* The stimula­
tion of mucus glycoprotein synthesis by propranolol, pronethalol and 
acebutolol is also at variance with earlier finding of their stimulatory 
effects on ethoxyresorufin 0-deethylase activity in rat hepatic microsoraes. 
These findings may be explained by the extent of gastrointestinal and
hepatic metabolism of the various compounds. Acebutolol and atenolol, 
by their 50$ gastrointestinal absorption (Kiechel and Meier, 1978)? maY 
undergo gastrointestinal metabolism leading to products which may cause 
changes in the mucosal cell endoplasmic reticulum and hence changes in 
the mucus glycoprotein synthesis. Pronethalol and propranolol are almost 
completely absorbed from the gastrointestinal tract and extensively meta­
bolized by the liver (Bond and Howe, 196?; Kiechel and Meier, 1978) to 
products that may stimulate mucus glycoprotein synthesis. Practolol on 
the other hand, does not show ready metabolism at either site (Keichel 
and Meier, 1978). Hence its long plasma half-life (Bodem and Chidsey,
1973; Reeves et_ al, 1978) and the ability of it or its metabolites to bind 
irreversible to microsomal fraction (Case e^t al^ , 1978) may result in the 
inhibition of protein Synthesis which could lead to the inhibition of glyco­
protein synthesis.
These findings suggest that the inhibition of mucus glycoprotein synthesis 
by practolol is peculiar to this particular beta-adrenergic blocking drug, 
since none of the other agents studied showed similar effects, and therefore 
cannot be explained by probable changes in cyclic nucleotide levels as a 
result of direct pharmocological effect of beta-blockade. The probable 
mechanism of action of practolol, in causing intestinal adhesion and 
obstruction (Nicholls, 1976), the ulceration of the cornea of the eye, oral 
and nasal mucosae (Wright, 1975; Rahi et al, 1976) as well as psoriasiform 
changes in the skin (Felix and Ive, 1974), may be through qualitative and 
quantitative changes in glycoprotein synthesis, as a result of high plasma 
levels of the drug on prolonged high dosage.
CHAPTER FIVE
EFFECT OF SOME BETA-ADRENERGIC BLOCKING AGENTS 
ON RAT TISSUE ADENYLATE CYCLASE/CYCLIC AMP 
AND GUANYLATE CYCLASE/CYCLIC GMP LEVELS
INTRODUCTION
The properties of adenylate cyclase, the enzyme which catalyses the 
formation of cyclic AMP within the cell have been reported to differ in 
several malignant tissues(Ney elt jal, 19&9? Brown et al, 1970, Dexter and 
Allen, 1971; Allen ejt al_, 1971; Schorr and Ney, 1971? Eaanelot and Bos, 
1971) or cells (Nakraan, 1971; Peery et al, 1971) from the activity of their 
normal counterparts. There are indications that the more anaplastic the 
cancer the lower is the activity of adenylate cyclase and the less it 
responds to the physiological stimulators such as hormones (Allen et al, 
1971, Emraelot and Bos, 1971; Makraan, 1971). However, not all observations 
lend support to this scheme (Brown jet al, 1970; Schorr and Ney, 1971;
Peery et al, 1971) and the inter-relationships between adenylate cyclase 
levels and the onset of malignancy are not clear.
It has been suggested that many of the properties of malignantly trans­
formed cells are due to low levels of cyclic 3*5* AMP (Pastan ejt a_l, 1975)*
When transformed isolated cells or hepatoma cells in culture are treated
with cyclic AMP, the transformed cells change in appearance, resembling 
more closely the normal cells and grow more slowly (Pastan, 1975; Van 
Wijk et al, 1972). On the otherhand dibutyryl cyclic AMP has been shown 
to increase the frequency of cell transformation by oncogenic viruses 
(Smith et al, 1973)» and chemical carcinogenesis is associated with an 
increased responsiveness of adenylate cyclase to hormonal control (Boyd 
et al, 1974) so that a cascade effect magnifying the malignant transforma­
tion could result, especially in stressful conditions when the circulating 
catecholamines are high. Although the level of cyclic AMP of established 
tumours is always low and the hormonal responsiveness of their adenylate 
cyclase is not high (Boyd et al, 1974) increased levels of cyclic AMP
are characteristic of the initial malignant cell transformation. In 
keeping with this hypothesis is the observation that the tumour- 
promoting phorbol-esters, applied to mouse epidermis also produce an 
initial increase in cyclic AMP followed by a marked depression, then 
a second period of elevation (Grimm and Marks, 1974). At this same time 
the hormonal regulation of adenylate cyclase is largely lost, indicating 
that the tumour promoters have resulted in damage of the cell membrane, 
the site of the p>-adrenergic rieceptors of adenylate cyclase.
Recent work has suggested that the regulation of DNA synthesis and cell 
division is controlled by the ratio of cyclic AMP to cyclic GMP rather 
than by cyclic AMP alone. An increase of DNA synthesis which accompanies 
a reduction of the cyclic AMP/cyclic GMP ratio, is considered to be the 
most important effect of the phorbol ester promoters, rather than their 
inhibition of DNA repair mechanisms (Trosko et al, 1975)•
Guanylate cyclase, the enzyme which catalyses the conversion of GTP to 
cyclic GMP is found in virtually all mammalian cells (Hardman and 
Sutherland, 1969; White and Aurbach, 1969). A number of chemical 
carcinogens such as hydrazine (Vesely and Levey, 1977a»b), nitrosaraines 
and nitrosaraides (De Rubertis and Craven, 1976; Vesely et al, 1977;
Claflin et al, 1978), sodium azide (Kiraura et al, 1975) and butadiene 
diepoxide (Vesely and Levey, 1978) have been shown to stimulate guanylate 
cyclase activity. These findings are of significant importance in chemically 
induced carcinogenesis, since cyclic GMP has been associated with cell 
proliferation, cell growth and malignant transformation (Hadden et^  al, 1972; 
Kram and Tomkins, 1973; Vesely et al, 1976).
Recent studies have demonstrated that aromatic amines,oC-halo esthers, 
polycyclic hydrocarbons, azo dyes and aflatoxins significantly decreased
guanylate cyclase activity (Vesely et al, 1978) which is in contrast to 
the other carcinogens, mentioned earlier, which increased guanylate cyclase 
activity. Thus, among these broad groups of chemical carcinogens there 
appears to be divergent effects on guanylate cyclase activity and tissue 
levels of cyclic GMP. However many carcinogens which stimulate guanylate 
cyclase activity, increase DNA synthesis (Banks et al, 1967? Saito and 
Sugimura, 1973)» whereas many of the carcinogens which decrease guanylate 
cyclase activity decrease DNA or RNA synthesis (Alfred and Di Paolo, 1968; 
Clifford and Rees, 1967; De Recondo et al, 1966; Grunberger et al, 1973; 
Jenssen et al, 1963; Kidsom and Kirby, 1965; Price et al, 19^9; Zieve, 1972) 
In light of the evidence, it appears that a relationship between cyclic GMP, 
DNA and RNA synthesis and chemical carcinogenesis cannot be excluded.
Beta-adrenergic blocking agents are known to block the stimulating effect 
of adrenaline and other catecholamines by competing with them for the 
active site of the enzyme adenylate cyclase (Fitzgerald and Barrett, 1967). 
This has led to the suggestion that these agents may act at the adenylate 
cyclase level giving rise to a reduction in cellular cyclic AMP levels.
It was therefore of interest to investigate the effects of some of these 
agents iji vivo on adenylate cyclase/cyclic AMP and guanylate cyclase/ 
cyclic GMP levels in various tissues of the rat.
EXPERIMENTAL
Materials
Theophylline, caffeine, creatine phosphokinase (EC 2.7.3.2), bovine 
serum albumin (BSA), creatine phosphate, alumina (grade 1) phosphoenol- 
pyruvate, pyruvate kinase (EC 2.7*1.40) and cyclic GMP were obtained from 
Sigma Chemical Co, London. The radiolabelled compounds [8-^^cjATP, |S-^ Hj 
cyclic AMP, cyclic GMP, !&-^c3 GTP and the radioimmunoassay (RIA)
kits of cyclic AMP and cyclic GMP were obtained from The Radiochemical 
Centre, Amershara, England. Insta-Gel and dimilume-30 were from Packard 
Instrument Company, Reading, England. Fluorescent cellulose coated thin- 
layer chromatography (TLC) plates (DC-Fertigplatten cellulose F) and all 
other chemicals were obtained from British Drug Houses (BDH) Ltd., Poole, 
England.
Animals and Treatment
Male Vistar albino rats (l40 - l60g) were kept in groups of four and 
fed ad libitum on Spratt*s laboratory chow. Test animals were dosed with 
compounds (15° mg/kg/day) for five days (Iral/lOOg body vt.) and control 
animals received equivalent amount of vehicle; water in case of propranolol 
acebutolol and pronethalol and 0.1M citric acid/Na^HPO^ buffer pH6.5 for 
practolol and atenolol. Animals were killed by cervical dislocation five 
hours after administration of last dose and tissues removed immediately 
and processed.
Enzyme Assays
The assay of adenylate cyclase and guanylate cyclase activities is based
fl4 Ion the conversion of^ CJ-labelled ATP and GTP respectively into their
corre sponding L cj -labelled 3 ' 5 t cyclic nucleotides which are then
isolated by column chromatography and determined by liquid scintillation
counting.
Tissue preparation
The preparation of liver horaogenates was according to the method of 
Vesely jet jal (1977) and that of gastric and intestinal mucosa by a 
modification of the method of De Rubertis and Craven (1977) used for 
the extraction of cyclic nucleotides (Figs. 5*1 and 5«2).
Guanylate cyclase assay
Guanylate cyclase activity was assayed by the original method of White 
and Zenser (1971) as modified by Vesely et al (1977) using GTP
as the enzyme substrate.
Solution
Cyclic GMP (13.35«M)
Caffeine (200raM)
BSA
Creatine phosphokinase (11.5 I-U.)
Creatine phosphate (50raM)
Buffer (20mM Tris-BCl.pH7«6)
[ 8 - l4 c ]  GTP (0 .152mM)
MnCl (60mM)
Tissue homogenate (lO-30mg/ml)
Volume/tube Wt/tube
(hi ) (mg)
20.0*
10.0*
0.1*
0.1*
10.0*
10.0*
20.0*
10.0+
20.0
Total 100.0 0.2
Livers
Homogenization
Centrifugation 
10,000rpra for 10 rains, at
lOOmg/ral Tris-HCI buffer 
(30mM) pH 7.6
4°C
(Use of MSE 8 x 
50 ml rotor)
Centrifugation 
l8,000rpra for 15 rains, at 4 C
Supernatant
discarded
Sediment washed and 
resuspended in same 
volume of buffer
Sediment
discarded
Supernatent
Used for Guanylate 
cyclase assay and 
protein determination
Centrifugation (MSE 8 x 50ml rotor) 
lOjOOOrpra for 10 mins. at 4 C
Supernatant
discarded
Sediment resuspended 
in same volume of buffer
Used for Adenylate 
cyclase assay and 
protein determination
Fig. 5*1 - Preparation of liver homogenate for Adenylate and
Guanylate cyclase assays
EDTA (0.133M) pH 7.6 lQul added after period of incubation at 
o
37 C to stop reaction.
* Mixed together and 7CU1 used per tube
<L . / \ o .
’ Preincubated with mixture (*) at 37 C for 5 minutes prior to 
addition of tissue homogenate.
After stopping the reaction with EDTA, the tubes were placed in a
boiling water bath for 3 minutes, to kill the enzyme, and kept at
«20°C overnight. The contents were thawed at room temperature and
distilled water (l ml) was added to each tube. Approximately 50*000 cpm
(j8-^ h]} cyclic GMP were added, to monitor per cent recovery, vortex-mixed
and centrifuged at 3*000 rpra for 15 minutes at 4°C. The supernatent was
put onto a column (0.4 x 10 cm) containing lg alumina prewashed with 50mM
Tris-HCl buffer pH 7-6 (15 ®l) and allowed to drain into the column. The 
(3ml)
eluate^was collected into glass vials and 2 mis used for scintillation 
counting after addition of Insta-Gel (15 ml) as liquid scintillant. Blanks 
were prepared using equivalent volumes of denatured enzyme protein.
Adenylate cyclase assay
Adenylate cyclase activity was assayed by a modification of the method of 
Krishna et al (1968) using (8-*4c3 ATP as the enzyme substrate.
Solution Volume/tube Wt./tub.
(mg)
KCI (260raM) 10.0*
Theophylline (80mM) 10.0*
BSA 0.0.8*
Pyruvate Kinase (4mg/ral) 5.0*
Phosphoenolpyruvate (l8mM) 5.0*
Buffer (20tnM Tris HC1 pH 7 .6) 10.0*
[ 8 - l4 c ]  ATP (0.139mM) 3 0.0 *
MgCl2 (30mM) 10.0+
Tissue homogenate (lo-£Orrcj/ml) 20.0
Total 100.0 0 .0 8
Stomach Intestine (15cm from stomach)
Cut longitudinallyCut along greater curvature
Contents washed with 1.15%(v/v) KC1 (ice-cold)
Tissues put in Tris-HCl buffer (50mM) pH 7*6 
(750 mg/ml)
Mucosae scraped into buffer
Homogeni zation
Centrifugation at 40,000 rpra for 40 mins at 4 C 
(Beckman Ultracentrifuge Model LS-6 5) 8 x 25®1 rotor
Supernatant
discarded
Sediment washed and 
resuspended in same volume of buffer
Centrifugation at 40,000 rpra 
for 40 mins at 4 C
Supernatent Sediment resuspended 
discarded in same volume of buffer
Used for Adenylate cyclase 
Guanylate cyclase and protein 
determinations
Fig. 5*2 - Preparation of gastric and intestinal mucosal homogenate
for Adenylate and Guanylate cyclase assays
EDTA (0.133*0 pH7*6 - lOjul added after period of incubation at
37°C to stop reaction,
* Mixed together and 70ul used per tube
*Preincubated with mixture (*) at 37°C for 5 minutes prior to 
addition of tissue horaogenate.
After stopping the reaction, the same procedure was followed as for 
guanylate cyclase except that 50*000 cpra [8-V] cyclic AMP were added 
to measure per cent recovery. Blanks were prepared using equivalent volumes 
of denatured enzyme protein.
Cyclic Nucleotide Assay
The assay of cyclic AMP and cyclic GMP is based on the competition between 
unlabelled cyclic nucleotide and a fixed quantity of the tritium labelled 
compound for binding to a protein/antiserum which has a high specificity 
and affinity for cyclic nucleotides. The amount of labelled protein/ 
antiserum-cyclic nucleotide complex formed is inversely related to the 
amount of unlabelled cyclic nucleotide present in the assay sample. Measure­
ment of protein/antibody-bound radioactivity enables the amount of unlabelled 
cyclic nucleotide in the sample to be calculated. Typical calibration 
curves for cyclic nucleotides are shown (Fig. 5*^0 •
Tissue preparation and extraction
The tissues were prepared by the method of De Rubertis and Craven (1977) 
and the cyclic nucleotides extracted by a modification of the acidic methanol 
method described in the product information pamphlet, Radiochemical Centre, 
Amersham, England (1977) on cyclic AMP and cyclic GMP (RIA) kits (Fig. 5*3)-
Cyclic AMP assay
The method used is as described in the pamphlet after Gilman (1970) and
Stomach and Intestine (l5cm)
Addition to each stomach/ 
intestine, 5ral Krebs-Ringer 
bicarbonate buffer pH7*4 
containing lmg/ml BSA and 
glucose and 10mM theophylline
Oxygenation [95%02:^^C^ J  
for 15 mins.
Mucosae scraped on filter paper 
soaked with ice cold saline
Mucosae of each stomach/intestine 
put in 2,5ml Krebs-Ringer 
bicarbonate buffer pH 7*4
and 5 rai acidic ethanol
Liver (0.25g)
Addition of 5®1 Krebs-Ringer 
bicarbonate buffer pH 7*4
Oxygenation [$5^2:^'C02-I 
for 15 rains.
Addition of 2.5 ml of fresh 
Krebs-Ringer bicarbonate 
buffer pH 7*4
Addition of 5“! acidic ethanol 
|jL:2(v/v) in HCItabsolute alcoholj
Homogenized and kept at room temperature for 10 mins 
Centrifugation at 3,000 rpm for 20 rains at 4 C (MSE Mistral 6L centrifuge)
1st supernatant saved Sediment resuspended in aqueous ethanol (2*5^ 1)
|jL:2(v/v) H^O:absolute alcohol]
1
Centrifugation at 3*000 rpm for 20 rains at 4 C
2nd supernatant saved Sediment
Mixed and 2ml evaporated to dryness 
at 55 C under stream of
Used for protein assay
Addition of 0.5ml Tris-HCl buffer (0.05M) pH 7*5 containing 5mM EDTA
Used for tissue cyclic AMP and GMP determinations
Fig. 5*3 - Extraction of tissue cyclic nucleotides
Brown et al (1971)-
Assay tube
Buffer
Oil)
Standards
(nl)
Unknown
(nl)
[j^ h J cyclic 
AMP 
(nl)
Binding
protein
(nl)
Charcoal blank 150 - - 30 -
Zero dose 50 - - 50 100
Standard 
(0-l6 pmol/tube)
- 50 - 50 100
Unknown - - 50 50 100
Buffer - Tris-H€l buffer (0.05M) pH 7-5 containing 4mM EDTA 
(8-^hJcyclic AMP - 18 pmol/ml containing approx. 5nCi 
Cyclic AMP Standard - 320 pmol/ml
The additions were done in the order shown above. After the last 
addition, the tubes were vortex-mixed for about 5 seconds, put in an 
ice-bath and placed in a cold-room at 4°C for 2 hours. Charcoal 
suspension (lOOjul) was added to each tube, vortex-mixed and replaced 
into ice-bath. The tubes were centrifuged 5 minutes after addition of 
charcoal suspension to the le^ st tube at 2,000 rpm for 60 minutes at 4°C. 
Aliquots (200nl) were removed from each tube without disturbing the 
sediment, placed into plastic scintillation vials containing dimilume- 
30 (5mls) as liquid scintillant. The vials were counted in the LKB 
Wallac Ultrabeta 2002 scintillation counter for radioactivity. The 
cyclic AMP content of unknown was calculated using the calibration 
curve for cyclic AMP.
Cyclic GMP assay
The method was as described for cyclic GMP in the pamphlet of The 
Radiochemical Centre, Amersham, England (1977) on cyclic GMP (RIA) kit.
Assay tube
[3h] cyclic GMP 
(hi)
Buffer
(hi)
Standard
(hi)
Unknown
(hi)
Blank
(hi)
Anti serum 
(hi)
Zero dose 50 100 - - - 50
Blank 50 - - - 100 50
Standard 
(0-8 pmol/tube) 50 _ 100 — 50
Unknown 50 - - 100 50
Buffer «= Tris—HCl (0.05M) pH 7*5 containing 4mM EDTA 
& - 3»] cyclic GMP - 8 pmol/ml H O containing approx. 1.6 nCi 
Cyclic GMP standard - 80 pmol/ml H O
The additions were as shown above. After addition of the antiserura the
tubes were vortex-mixed for 5 seconds and placed in ice-bath and kept at
2-4°C for l|- hours. Ice-cold saturated (NH^)^ SO^ solution (l ml) was added
to each tube, capped and vortex-mixed for a few seconds. The tubes were
replaced in the ice-bath and allowed to stand for 5 minutes (timed from
the addition of (NH^)^ SO^ to the last assay tube). The tubes were then
centrifuged at 2,000 rpm for 30 minutes at 4°C and the supematent decanted.
The tubes were made to stand upside down on tissue paper to drain. Any
excess liquid from the neck of each tube was wiped carefully by a piece of
tissue taking care not to disturb the precipitate. Distilled water (l.l ml)was 
and 1ml
added to each tube,mixed,/, removed into glass vials and dimilume-30 (10 ml) added to 
each vial as liquid scintillant. The counting was done as for cyclic AMP and 
the cyclic GMP content of unknown calculated using the calibration curve for 
cyclic GMP.
2 14 
H - C.dual labelling
Separate channels were set for and counting.[^liJ-and w -
hexadecane standards (lOjJleach) were put into scintillation vials,
in duplicate, containing Insta-Gel (15ml) as liquid scintillant and
30njM Tris-KCl buffer pH 7.6 (2ral). The counting efficiencies in each 
3 14channel for H and C were determined and used to calculate per cent 
recoveries of cyclic nucleotides formed in guanylate and adenylate cyclase 
assays. The mean per cent recoveries obtained in experiments were;
Cyclic AMP 95 + 15
Cyclic GMP - 6 0 + 1 0
. . Tl4 1 .Identification of L CJ cyclic nucleotide products
R4lThe L CJ-containing products were identified as cyclic AMP and cyclic 
GMP as determined by TLC using 1 M formic afcid, 1 M LiCl as solvent
a
system and developed with absolute alcoholol and concentrated NH^OH 
(5*2 v/v) using [^h J cyclic AMP and GMP as standards. The developed 
spots were identified under fluorescence.
Protein Assay
The protein content of the various tissue homogenates were determined 
by the method of Lowry ejt al_ (1951)-
Calculation of Enzyme Activity
The activities of adenylate and guanylate cyclases were calculated 
according to the formula;
S - B x M x 100 
SD P % Recovery
expressed as pmol cyclic nucleotide formed/mg protein/ time of incubation
Where S = Sample cpm M
B = Blank cpm
P
SD = Standard cpm
Concentration of standard 
(paol/tube)
Enzyme protein concentration 
(mg/tube)
RESULTS
Effect of Time of Incubation on Production of Cyclic Nucleotides
The production of cyclic GMP increased with incubation time in a 
linear fashion for all the tissues studied whilst the production of 
cyclic AMP increased non-linearly with time of incubation (Figs. 5*5 and 
5.6).
Effect of Pretreatment with Beta-adrenergic Blocking Agents on Rat 
Tissue Adenylate and Guanylate Cyclase Activities
Practolol and atenolol gave rise to marked and concomitant increases in 
both adenylate and guanylate cyclase activities in all three tissues. This 
is reflected in the absence of any significant changes in the ratios of 
adenylate cyclase activity (ACA)/guanylate cyclase activity (GCA) before 
and after pretreatment with these agents. Pronethalol preferentially 
increased adenylate cyclase activity of the liver and gastric mucosa 
whilst causing concomitant increases in both adenylate and guanylate 
cyclase activities in the intestinal mucosa, as indicated by the ratios 
of adenylate/guanylate cyclases before and after pretreatraent. Propranolol 
and acebutolol on the otherhand, preferentially increased guanylate 
cyclase activity in the tissues as shown by the decrease in the ratios 
of adenylate/guanylate cyclases after pretreatment with the compounds. 
(Tables.5.1 - 5*5).
Effect of Pretreatment with Beta-adrenergic Blocking Agents on Rat .
Tissue Cyclic Nucleotides Levels
The beta-adrenergic blocking agents, practolol and atenolol, did not 
significantly affect the levels of cyclic AMP and GMP in the three tissues. 
This is indicated by the similarities in the ratios of cyclic AMP (C-AMP)/
cyclic GMP (C-GMP) before and after pretreatraent. Pronethalol on the 
otherhand gave rise to concomitant decreases in cyclic AMP and GMP levels 
in gastric and intestinal mucosa as shown by the absence of any significant 
changes in the ratios of C-AMP/C-GMP on pretreatment. Propranolol markedly 
decreased the level of cyclic GMP in intestinal mucosa whilst acebutolol 
gave rise to a marked decrease in the cyclic AMP level of the liver (Tables
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DISCUSSION
Recent studies have shown that most chemical carcinogens produce 
marked increases in hepatic and gastrointestinal mucosal guanylate 
cyclase and cyclic GMP levels without concomitant increases in adenylate 
cyclase and cyclic AMP levels (De Rubertis and Craven, 1976; Vesely and 
Levy, 1977 a, b; Vesely et al, 1977)* However the concomitant increases 
in guanylate and adenylate cyclase activities and decreases in cyclic 
nucleotide levels, in the various tissues studied, caused by the beta- 
adrenergic blocking agents is at variance with the above observations for 
chemical carcinogens.
It has been suggested that beta-adrenergic blocking agents may 
competitively inhibit the effects of catecholamines by acting at the 
adenylate cyclase level. The stimulation of tissue adenylate cyclase by 
all the compounds studied, appear to suggest the involvement of beta- 
blockade in the activation of adenylate cyclase. A plausible explana­
tion is that the beta-blockade of a membrane beta-adrenergic receptor 
dependent GTP-ase may prevent the conversion of GTP to GMP which is an 
important step in the deactivation of adenylate cyclase as has been 
suggested for propranolol with plasma membrane (Levitzki, 1977; Cassel 
and Selinger, 1976, 1977)*
The stimulatory effect of these agents on tissue levels of adenylate 
cyclase was in the order, pronethalol>atenolol>practolol>propranolol> 
acebutolol. The trend shown by the less lipid-soluble beta-adrenergic 
blocking agents, practolol, atenolol and acebutolol, may be due to a 
culmination of three factors namely; beta-blockade potency (waal-Manning, 
1976b), degree of GIT absorptivity (Meier et al, 1977) and elimination
half-life (Bodem and Chidsey, 1973; Reeves et al, 1978; Brown et al, 
i976; Steyn, 1976). The propranolol effect may be the result of its 
extensive liver metabolism and Mfirst-passM effect and shorter elimina­
tion half-life (Shand, 197^; Meier et al, 1977) leading to a reduction 
in its beta-blockade effect. The marked stimulation by pronethalol may 
be due to a culmination of its beta-blockade effect and the formation of 
products with a stimulatory action on adenylate cyclase. Although 
practolol, atenolol and to some extent acebutolol act preferentially 
on the ^-adrenoceptors, at the dosage of 150 mg/kg used in this study 
they also affect the ft -adrenoceptors (Lertora et hi, 1975) and hence
w
their effects on the peripheral tissues.
One of the characteristics of malignantly transformed cells is that they 
contain reduced levels of cyclic AMP and elevated levels of cyclic GMP 
leading to reduction in C-AMP/C-GMP,ratio. (Stevens et al, 1978). There 
are conflicting reports on the influence of cyclic AMP and GMP phosphodi­
esterase activities on the levels of these cyclic nucleotides (De Rubertis 
et al, 1976; Stevens et al, 1979)* The increased levels in tissue adenylate 
and guanylate cyclase after administration of the beta-adrenergic blocking 
agents, should of consequence give rise to increases in cyclic AMP and GMP 
levels. However, the parallel decreases in the levels of these cyclic 
nucleotides after pretreatment with these agents suggests the regulation 
of their levels through increased cyclic AMP and GMP phosphodiesterase 
activities of which the former has been suggested to be increased by the 
tumour-promoting agent, 1,2-dimethylhydrazine(Stevens et al, 1979)* There 
was also no direct relationship between the ratios of adenylate/guanylate 
cyclases and C-AMP/C-GMP or their individual levels before and after pre­
treatment with the agents. These findings indicate that none of the agents 
displayed the characteristics of tumour-promoting agents as suggested for the .
phorbol eaters by Trosko et al (1975)»
It has been suggested that carcinogens may cause the inhibition of 
glycoprotein synthesis through degranulation of the endoplasmic 
reticulum (Parke, 1977b)• The lowering of tissue cyclic AMP.or ratio 
of C-AMP/C-GMP has been associated with the inhibition of glycoprotein 
synthesis (Hepp, 1972; Solderling et el, 1973? Macdonald et al, 1977) 
and hence may lead to increased incidence of tumours. The effects shown 
by the beta-adrenergic blocking agents on ratios of a adenylate/guanylate 
cyclases and C-AMP/C-GMP in the various tissues, did not cause marked 
inhibition of glycoprotein synthesis with the exception of practolol 
(Chapter 4 ). These observations suggest that the ratios of adenylate/ 
guanylate cyclases and C-AMP/C-GMP alone may not cause the inhibition of 
glycoprotein synthesis. Hence the tumour-promoting potential of these 
agents does not involve the inhibition of glycoprotein synthesis through 
changes in tissue adenylate cyclase/C-AMP and guanylate cyclase/C-GMP levels.
It thus appears that the effects of the beta-adrenergic blocking agents on 
the various parameters studied are to some extent the result of direct 
pharmacological effect of beta-blockade and are uncharacteristic of those 
exhibited by known tumour-promoting agents, suggesting that their mechanism 
of action as possible potential tumour promoters does not involve changes in 
tissue levels adenylate cyclase/C-AMP and guanylate/C-GMP.
CHAPTER SIX 
GENERAL DISCUSSION
GENERAL DISCUSSION 
Beta-adrenergic Blocking Agents in Short-term Mutagenicity Test
The deactivation of drugs and detoxication of environmental chemicals is 
brought about by microsomaT mixed-function oxygenase system (Parke, 1968) • 
The microsomal oxygenation, by the mixed-function oxygenases, of many 
compounds e.g. polycyclic aromatic hydrocarbons lead to the formation, of 
reactivevmetabolites (Grover and Sims, 1968; Gelbion, 1969; Oesch et al, 
1972). These metabolites are electrophilic in character and attack the 
nucleophilic centres of DNA and other biological macromolecules (Miller 
and Miller, 1969* 1971; Weisburger, 1973; Heidelberger, 1973)* These 
reactions are believed to form the basis of the mutagenicity of these 
reactive metabolites.
There is considerable evidence in support of a correlation between 
carcinogenesis and mutagenesis (Miller and Miller, 1975; Ames £t al,
1975; McCann et al, 1975; Purchase jet sal, 1978; Bartsch et al, I98O; 
Jenssen and Ramel, I98O), suggesting a common molecular mechanism for 
these two processes (Brusick, 1977)* This has led to the development of 
fast and less expensive in vitro assay systems demonstrating mutagenic 
activity, for the identification of potential chemical carcinogens. How­
ever there are some carcinogens which are not mutagenic probably because 
they are not metabolized to reactive intermediates in these test systems 
or act via a different mechanism of carcinogenesis i.e. epigenetic mecha­
nisms.
A combination of the in. vitro Ames' bacterial and the iti vivo mammalian 
micronucleus tests has been shown to provide a more sensitive system with 
higher predictive value for the identification of mutagenic carcinogens 
(jenssen and Ramel,l<?8o) . The in vivo assay system is able to detect also , the
breakage and non-disjunction of chromosomes. It also helps to over­
come the imbalance between the activating and deactivating metabolism 
in vitro with the S - 9 mix in the Ames test which affects its sensitivity 
(Ashby and Styles, 1978)*
The fact that none of the beta-adrenergic blocking agents studied pro­
duced positive results in the Ames and micronucleus tests, indicates their 
non-mutagenic character. However, the bacteriocidal action of oxprenolol 
and propranolol, in the absence of S-9 mix in the Ames test, together with 
the increases in the number of raicronuclei, above the spontaneous control 
level in the micronucleus test, may involve the breakage or non-disjunction 
of chromosomes which could result from mechanisms other than chemical inter­
action with DMA as suggested for saccharin by Bateman and Epstein (1971)*
The epoxidation of the allyloxy side chain of oxprenolol in mice, may be 
responsible for its chromosomal effects.
Beta-adrenergic Blocking Agents and Short-term Carcinogenicity Tests
Some carcinogens exert their action at sites other than DNA and these 
may explain why compounds such as DDT, chloroform and saccharin, amongst 
others, gave negative results in the Ames test (Uehleke et al, 1977j 
McCann and Ames, 1976; Marshall et al, 1976; Ashby et al, 1978). These 
compounds are termed epigenetic carcinogens (Williams, 1977) and the 
investigation of their sites of action coupled with the development of 
other test systems, which do not involve chemical interaction with DNA, 
is of great importance for the detection of such carcinogens.
One of the sites of action of carcinogens is the rough endoplasmic 
reticulum culminating in the degranulation of the endoplasmic reticulum 
(Gustafsson and Afzelius, 1963)* This offers a possible means of carcino­
genicity testing of epigenetic carcinogens, at the cellular level. This
effect has been observed in vivo by electron microscopy (Posner et al,
1961; Orrenius, 19&5) anc* demonstrated in vitro by the measurement of 
disulphide rearrangease, which increases in activity with the degree of 
degranulation (Williams and Rabin, 1971; Williams and Parry, 1975; Dani 
et al, 1976). The pattern of protein synthesis would be affected as a 
result.of extensive degranulation e.g. glycoprotein synthesis which 
normally occurs only in the endoplasmic reticular bound ribosomes 
(Halliran et al, 1968) would become inhibited as a result of degranula­
tion of the endoplasmic reticulum and at the same time an increase in 
intracellular protein production may occur resulting in cancer formation 
and major physiological changes (Parke, 1977c, 1979)•
The in vitro "degranulation" technique has been developed and a good 
correlation exists between various in vivo carcinogenicity tests and the 
degree of degranulation obtained (Wright et al, 1977)* The use of human 
liver preparations for this test and the Ames test could provide more 
meaningful information as to the action of a variety of suspect carcinogens 
in man.
The biphenyl system offers an alternative possibility as a screening test 
for epigenetic carcinogens since the action of carcinogens on this system 
is also at the endoplasmic reticulum level. The degranulation of the 
endoplasmic reticulum and the stimulation of biphenyl 2-hydroxylase 
activity, caused^.carcinogens, have been suggested to be a related process 
(Parke, 1976). However, a direct relationship does not exist since the 
stimulation of biphenyl 2-hydroxylase required a much shorter period to 
attain maximal effect (McPherson et al, 1976). Also agents such as EDTA, 
which cause extensive degranulation of the endoplasmic reticulum (Rabin 
et al, 1971; Lin and Farber, 1977) > failed to have an effect on biphenyl
2-hydroxylase (McPherson et al, 1974)i although the cytotoxic effect 
of EDTA may lead to complete disruption of the endoplasmic reticulum and 
its constituent enzymes*
Pretreatment of animals with carcinogens, e.g. 3-methylcholanthrene, 
has been shown to stimulate the cytochrome P-448—mediated microsomal 
enzymes such as biphenyl 2- and 4- hydroxylases and ethoxyresorufin 0- 
deethylase (Burke and Mayer, 1975; Bridges et al, 1973; Burke et al, 1977; 
Atlas and Nebert, 1976). Hence the measurement of these enzymic parameters 
after pretreatment with test compounds can provide useful information as to 
their carcinogenicity potential. Also the problem of interferance of
fluorescent metabolites of test compounds in the in vitro system in the
/
measurement of 2- and 4-hydroxybiphenyls, as shown for 3-nethylcholanthrene, 
3,4, benzo(a) pyrene and safirole (Tong, 1979)» would be reduced or eliminated 
in the iji vivo situation.
The stimulation of the cytochrome P-448-raediated enzymic parameters, 
particularly of ethoxyresorufin O-deethylase activity, by beta-adrenergic 
blocking agents depends on the lipophilicity of the agents with the most 
lipid-soluble ones showing the most stimulation in the order, propranolol> 
pronethalol>acebutolol>atenolol and practolol. The levels of stimulation 
of these cytochrome P-448-mediated enzymic parameters by propranolol and 
pronethalol at very high dosage are similar to those shown by DDT and
fied as epigenetic carcinogens. These results compare similarly to. those 
of long-term animal carcinogenicity tests for pronethalol (Paget, 19^3; 
Alcock and Bond, 1964; Howe, I965) and propranolol (Smith and Butler, 197&; 
Boyd and Martin, 1977)? suggesting the possibility of propranolol and 
pronethalol acting via epigenetic mechanisms as potential tumour promoters.
saccharin [[Tong, 1979; Tong, 1979 (Unpublished
Microsomal Enzyme Induction by Beta-adrenergic Blocking Agents 
and Chemical Interactions
Short-term administration of pronethalol and propranolol at very high 
dosage, induced cytochrome P-448 resulting in the stimulation of the mixed- 
function oxidations it catalyses in the rat liver. The possibility of the 
marked induction of cytochrome P-448 by these agents on prolonged high dosage 
is not overruled and this may have long-term implications in man. High drug- 
raetabolizing enzyme activities as a result of enzyme induction may be bene­
ficial if the foreign compound is rendered inactive, but harmful when toxic 
metabolites are produced. Thus the induction of cytochrome P-448 by prop­
ranolol and pronethalol on prolonged high dosage in man may exert a pro­
found influence on their own rates and modes of metabolism as well as other 
chemicals, such as food additives, that are generally present in human diet, 
leading to production of adverse reactions including the formation of tumours.
Apart from the mixed-function oxygenase system which metabolizes xenobiotics,
there are a number of other enzymes in the cell e.g. epoxide hydrase and
glutathione S-transferase, which exert a significant influence on the fate
of foreign compounds in the animal body. Epoxide hydrase {Oesch et al, 1972)
reticulum
which transforms epoxides into dihydrodiols, is located in the endoplasmic/ 
whilst glutathione S-transferase (Hayakawa et ajL, 1975) which metabolizes 
diols or phenols into soluble conjugates, is found in the cytoplasm of the 
cell. These enzymes therefore convert mutagenic electrophilie intermediates 
into non-toxic substances that do not react with biological macromolecules.
Thus if epoxide hydrase activity is greater than the rate of conversion of 
a carcinogen to its reactive intermediate by the mixed-function oxygenases, 
toxic effects may not be produced. Hence any evaluation of the safety of 
compounds such as beta-adrenergic blocking agents must take into account the 
implications of microsomal enzyme induction.
Adenylate Cyclase/Cyclic AMP and Guanylate Cvclase/Cyclic GMP 
Levels and Toxicity of Beta-adrenergic Blocking Agents
The properties of adenylate cyclase have been reported to differ in several 
malignant tissues of cells from their normal counterparts (Ney al, 1969; 
Allen et al, 1971; Emraelot and Bos, 1971; Makman, 1971; Peery e£ al, 1971)*
The competitive inhibition of the stimulating effects of catecholamines 
by beta-adrenergic blocking agents at the adenylate cyclase level (Fitzgerald 
and Barrett, 1967)* However, the activation of tissue adenylate cyclase after 
pretreatment of rats with these agents, may be explained by their possible 
inhibition of the membrane beta-adrenergic receptor GTP-ase which converts 
GTP to GMP; an important step in the deactivation of adenylate cyclase.
This has been proved with plasma membrane using propranolol (Levitzki, 1977; 
Cassel and Selinger, 1976, 1977)- This stimulatory effect of these agents • 
depends on their beta-blockade potency (waal-Manning, 1976b), degree of GIT 
absorptivity (Meier ^ t al, 1977) and elimination half-life (Bodera and Chidsey, 
1973; Reeves et al, 197$; Brown et al, 1976; Steyn, 1976). However this 
stimulatory effect is at variance with the decreased levels of this enzyme 
in anaplastic cancer cells, although the inter-relationship between the 
levels of this enzyme and the onset of malignancy is not clear (Allen et al, 
1971; Makman, 1971; Brown et al, 1970; Peery et al, 1971)•
Recent studies have shown that some carcinogens preferentially stimulated 
tissue guanylate cyclase activity as well as cyclic GMP level without 
significantly affecting the adenylate cyclase and cyclic AMP levels, such 
that the ratios of adenylate/guanylate cyclases and C-AMP/C-GMP are 
decreased (De Rubertis and Craven, 1976; Vesely and Levy, 1977 a,b; Vesely 
et al, 1977)* One of the characteristics of malignantly transformed cells 
is that they contain decreased levels of cyclic AMP and elevated levels of 
cyclic GMP and hence reduced ratio of C-AMP/C-GMP(Stevens et al, 197^).
There are conflicting reports on the levels of these cyclic nucleotides 
(De Rubertis et al, 1976; Stevens et al, 1 9 7 9 )« The absence of any direct 
relationship between the ratios of tissue adenylate/guanylate cyclases 
and C-AMP/C-GMP after pretreatment with the beta-adrenergic blocking agents 
implicates phosphodiesterase activity in the regulation of tissue cyclic 
AMP and GMP levels.
The role of adrenergic mechanisms in relation to gastric mucosal cyclic 
nucleotide levels have been investigated (Ruoff and Sewing, 1975) ancl has 
led to the suggestion that the rise in tissue cyclic AMP level on adrenaline 
administration is mediated by beta-adrenoceptors whilst that in tissue cyclic 
GMP level is mediated by alpha-adrenoceptors. Hence the lowering of tissue 
cyclic AMP levels is a result of direct pharmacological effect of beta- 
blockade as demonstrated by the beta-adrenergic blocking agents.
The activation of gastric mucosal adenylate cyclase appears to be an 
essential event during stimulation of acid secretion. This view and the 
finding of Ruoff and Sewing (1975) that no changes in phosphodiesterase 
activity of gastric mucosa occur after feeding and pentagastrin (adenylate 
cyclase stimulator) administration, is in contrast to proposals that gastric 
mucosal cyclic AMP levels are regulated by the changes in activity of this 
enzyme (Amer, 1972; Araer and McKinney, 19 7 2 ). The question as to whether 
activation of adenylate cyclase by gastric secretagogues lead to the 
elevation of gastric mucosal cyclic AMP concentration has been raised.
The effect of beta-adrenergic blocking agents on gastric acid secretion are 
conflicting. They have been shown to stimulate (Konturek and Oleksy, 1969; 
Evans and Lin, 1970), inhibit (Pradham and Wingate, 1962; Bass and Patterson, 
1967; Okabe et al, 1970; Gueraei et al_, 1972; Danhof and Guemei, 1972) or have 
no effect (Haigh and Stredman, 1968; Misker et al, 1969). Similar controversy
exists with regard to production of gastric ulcers. An increasing 
(Rosoff et al, 1968; Kohcut et al, 1970; Pfeiffer and Sethbhakdi, 1971) 
and decreasing (Okabe et al, 1970; Danhof and Gueraei, 1972; Takagi et al,
1964) incidence of gastric ulcers have been reported. In recent study by 
Debn&th jlL (1974) it was reported that the stiroulatory and inhibitory 
effects of propranolol on gastric acid secretion and ulceration in pyloric 
ligated rats was dose-dependent. Comparative study of the effects of 
propranolol, and practolol on basal gastric secretion (Goel et al, 1977) 
showed a dose-dependent effect on gastric secretion and ulceration. Smaller 
doses increased ulceration and higher doses decreased it. The probable action 
of these beta-adrenergic blocking agents may be that at high dosage, the 
activation of adenylate cyclase is counteracted by decreased levels of 
cyclic AMP resulting in decreased gastric secretion and hence reduced 
ulceration, whereas at low dosage there may be no significant change in 
cyclic AMP levels and thus increased adenylate cyclase activity leads to 
increased gastric secretion and hence increased ulceration.
A relationship has been shown between the inhibition of the rate of gastric 
mucus synthesis and the incidence of gastric erosions (Dekanski et al, 1975? 
Johnston et al, 1975)* Th« possibility of the involvement of cyclic 
nucleotides in mucus glycoprotein synthesis has been investigated by 
Macdonald jet al (1977)* After in vitro incubation of mucosal homogenate 
with dibutyryl analogues of cyclic AMP and GMP, a significant reduction of 
glycoprotein synthesis as measured by a reduction in the rate of incorpora-
Dibutyryl cyclic GMP gave no significant effects, while theophylline at a
significant effects. The levels of tissue cyclic AMP and adenylate cyclase,
tion of N-acetylglucosamine was observed with dibutyryl cyclic AMP
concentration of 10 gave similar effects to dibutyryl cyclic AMP. At - 
concentrations of dibutyryl cyclic AMP lower than 10*’4>I, there were no
as a result of beta-blockade, has no direct bearing on the rate of mucus 
glycoprotein synthesis as demonstrated by the beta-adrenergic blocking 
agents studied. This is at variance with the relationship of cyclic 
nucleotides and the incidence of gastric erosions, caused by increased 
gastric secretion as suggested by Goel et al (1977)*
Practolol Toxicity and the Inhibition of Glycoprotein Synthesis
Drugs may alter the rate of secretion of mucus, the chemical and physical 
structure of mucus or its rate of synthesis. They may thus affect the normal 
physiological functions of mucus and its protective effect on the epithelium 
resulting in therapeutic benefit or adverse drug reaction. Drugs not 
generally associated with diseases of epithelial tissue or abnormalities 
of mucus secretion may nevertheless have an effect on mucus. This is 
particularly likely with drugs that affect cellular metabolism, such as 
adrenaline and other beta-adrenergic agents, beta-adrenergic blocking 
agents, inhibitors of adenylate cyclase or phosphodiesterase, prostaglandins 
and so on (Parke, 1978). Most drugs having effects on mucus e.g. carbenoxo- 
lone and indoraethacin have been shown to cause qualitative and quantitative 
changes in mucus glycoprotein synthesis as measured by the rates of incor­
poration of radiolabelled amino acid and sugar precursors into rat gastro­
intestinal mucus glycoproteins (Shillingsford, 1975; Dekanski et al, 1975; 
Johnston et al, 1975)*
0
The practolol reaction, oculoraucocutaneous syndrone in man, culminated in 
the ulceration of the cornea of the eye, nasal and oral mucosae (Wright,
1975; Rahi et al, 1976) psoriasiform changes in the skin (Felix and Ive,
1974) as well as intestinal adhesions and obstructions (Nicholls, 1976).
Few observations to this effect have been reported for other beta-adrenergic 
blocking agents such as oxprenolol and propranolol (Holt and Vaddington, 1975
Cubey and Taylor, 1975)* However whether these effects are a direct 
result of beta-blockade or non-specific reactions is not known.
The peculiar inhibition of mucus glycoprotein synthesis by only practolol 
amongst the beta-adrenergic blocking agents studied rules out the general 
involvement of beta-blockade in mucus synthesis. Practolol has been shown 
to. be metabolized in vitro to metabolites which bind irreversibly to liver 
microsomes and this binding was highest with hamster raicrosoraes (Case et al 
1978). Recent study by Lindup et al, (1979) on the in vivo tissue binding 
of practolol and its metabolites in hamsters has led to the observation of 
a linear dose-dependent irreversible binding to the eye. However there was 
no observation of ocular toxicity after chronic administration to several 
animal species including hamsters. This binding of practolol or its 
metabolites to microsomes could result in cellular changes.* which may lead to 
the reduction of mucus glycoprotein synthesis probably by inhibiting the 
synthesis of protein which is the rate-limiting step in the glycosylation 
process. The observed inhibition of gastrointestinal mucus glycoprotein 
synthesis by practolol suggests its possible degranulation of the mucosal 
cell endoplasmic reticulum and hence the probable formation of gastrointestinal 
tumours which may explain the intestinal obstructions observed in humans by 
Nicholls (1976). The qualitative changes in glycoprotein synthesis by 
practolol, in response to its long plasma half-life on prolonged high 
dosage, may result in the formation of immunoglobulin Es (igEs), which 
are glycoprotein in nature, culminating in the psoriasiform changes in the 
skin.
Extrapolation of Toxicological Study of Beta-adrenergic Blocking 
Agents to Man
Different animal species can on occasions vary markedly in their response 
to drugs. This is important because laboratory animal species are commonly
used for the preclinical pharmacology testing and in particular for the 
safety evaluation of a new drug. Such species variations raise disturbing' 
problems, particularly where the most serious types of toxicity are 
concerned such as carcinogenicity and teratogenicity. Thalidomide, is 
teratogenic in the rabbit (Fabro and Smith, 1966) and the rat (King and 
Kendrick, 1962) but not in the hamster (Hague et_ jal, 1967)* The polycyclic 
aromatic hydrocarbon, 3-methylcholanthrene, is carcinogenic to various species 
such as the rat, mouse and tree shrew, but not in the rhesus monkey (Adamson, 
1972)• DDT has been reported to be a weak carcinogen in the mouse but 
not in the hamster (Wallcave et al, 1973)* These species variations there­
fore raise questions as to the adequacy of the animal model for the human 
situation.
Interspecies variations in response to toxic substances originate in 
differences in one or more of the following factors:- rate of absorption, 
binding to plasma proteins and other tissue macromolecules, the mode of 
excretion, the rate and route of metabolism and the responsive nature of 
the receptor. Of these, one of the most important is the metabolic factor; 
many cases of species differences in response to toxic substances in 
mammalian species arise from metabolic differences, particularly in the 
nature of the metabolic pathway. These species differences often arise 
because of interspecies variations in the amounts of active or toxic 
metabolites formed during the course of biotransformations.
Extensive metabolic studies of most beta-adrenergic blocking agents have 
been carried out in man and most animal 3pecies. This has led to the 
identification in rats of products that are identical to those found in man 
suggesting identical pathways of metabolism (Scales and Cosgrave, 1970;
Reeves et al, 1978; Bond, 19^7; Hayes and Copper, 197i> Leinweber et al,
1971; Bond and Howe, 1967; Brown et al, 1976 Steyn, 1976, Anderson and 
Davis, 1979; Tocco et al, 1980). Hence the possible justification of the 
use of the rat in the toxicological evaluation of beta-adrenergic blocking 
agents.
Recent* studies into the safety evaluation of industrial and environmental 
chemicals have indicated that many compounds are carcinogenic only in the 
mouse. Many of these chemicals are negative in the Ames test for muta­
genicity, implying their function as promoters of carcinogenesis (Epigenetic 
carcinogens).
The reason why carcinogenesis by this type of compound is so often seen 
only in mouse liver is probably because of some fundamental species 
abnormality in microsomal metabolism. A number of such abnormalities are 
seen with the mouse, which therefore makes it a most unsuitable species for 
monitoring carcinogenic potential, especially of promoters. Firstly, there 
is a high rate of hepatic microsomal metabolism in the mouse leading to 
greater generation of the active metabolite and hence greater damage to 
the endoplasmic reticulum, and greater potentiation of carcinogenesis, for 
a given dose of promoter. . Secondly, there is a greater predominance of 
the rough to smooth endoplasmic reticulum in the liver of mouse than in rat, 
guinea pig or monkey liver (Gram e^ t al, 1971)* Also, mouse liver contains 
much higher activities of mixed-function oxygenase in the rough endoplasmic 
reticulum than occurs in other species (Gram et al, 1971)* These features 
would suggest that the extent of degranulation of the endoplasmic reticulum 
for a given amount of active intermediate would be much greater in the mouse 
than in other species.
A further factor which may make the mouse more vulnerable to the action of 
promoters is the possible greater level of carcinogenesis initiation activity
The high rate of microsomal metabolism, consequent degranulation and 
hence carcinogen activation, would potentiate the effect of environmental 
mutagens so that a given dose would lead to greater DNA damage than occurs 
in other larger species. Furthermore, there is evidence that there is a 
much higher level of oncogenic viruses present in the mouse than in most 
other species. All these factors would explain the anomalous behaviour 
of the mouse in chemical carcinogenesis, and would indicate that the forma­
tion of hepatocellular carcinoma in this species, is a spurious index of 
the tone carcinogenic potential of these chemicals in other animal species 
including man.
Long-term carcinogenicity studies of pronethalol in rats, mice and guinea- 
pigs, have led to the identification of thymic tumours in mice but not in 
the other species (Paget, 1963; Alcock and Bond, 1964; Howe, 1965)* This 
led to the postulation of a hypothetical ethyleneimine derivative of 
pronethalol in mice as the proximate carcinogen responsible for the turaorigenic 
properties of pronethalol. This tumorigenicity potential observed in the mouse 
by pronethalol, and not in the other species, may be the result of the 
abnormalities in metabolism in the mouse.
Thus, although there is no evidence of tumorigenicity potential of beta- 
adrenergic blocking agents in man their probable induction of the mixed- 
function oxygenases, after prolonged high dosage, as demonstrated in the 
rat by pronethalol and propranolol, necessitates further studies in man 
since this may lead to chemical interactions resulting in adverse reactions 
including tumour formation. Also the anomalous inhibition of rat gastro­
intestinal mucus glycoprotein synthesis, irrespective of changes in cyclic 
nucleotide levels as a result of beta-blockade, by practolol may help 
explain the ulceration of the nasal and oral mucosae, the intestinal 
obstructions and adhesions, and probably the ulceration of the cornea of
the eye, in man after prolonged treatment. Hence the development of in 
vitro systems for the investigation of mucus glycoprotein synthesis with 
various human tissues would be of great interest.
It may be said that the mutagenic and epigenetic or enzyme induction 
studies have shown no major implications of the group of beta-blockers as 
a whole for mutagenicity or tumorigenicity, although there are indications 
for certain of these drugs. The cyclic nucleotide studies reveal no major 
adverse effects and the glycoprotein studies show that practolol is 
anomalous in its inhibitory effect, which may have some bearing on the 
mechanism of its known toxicity. In summary, the group of beta-blockers 
as a whole show no pattern of toxic or mutagenic effects, but specific 
drugs do show tendencies which at high tissue concentrations that may 
result from overdosage or impaired metabolism or excretion, might give 
rise to adverse side-effects in susceptible populations, especially those 
where genetic impairment of metabolism is present.
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